{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgJ7KkuUIDA","lastupdate":"2024-01-17T00:00:00.000Z","update_date":"2024-01-17T00:00:00.000Z","lastModified":"Oct 23, 2025","active":1,"confidence_score":90,"confidence_score_reason":"markets, not claimed","urlname":"enterabio","minimal_profile":null,"status":"Public","fullstatus":"Public on NASDAQ on Jul, 2018;","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$dPDIlWRLTZPzFYrk5wjDddJeYOndAY3kDe5t1AJyKWnS1JMBI8r5Dy","name":"Entera Bio","oneliner":"Oral Delivery of Therapeutic Proteins","registrar":"514330604","website":"https://enterabio.com","careerspage":"","founded_month":9,"founded_year":2009,"formernames":[],"sociallinks":{"twitter":"","youtube":"","facebook":"https://www.facebook.com/Entera-Bio-%D7%9E%D7%97%D7%A7%D7%A8-%D7%9C%D7%AA%D7%A8%D7%95%D7%A4%D7%94-%D7%91%D7%95%D7%A0%D7%AA-%D7%A2%D7%A6%D7%9D-101763397878419","linkedin":"https://www.linkedin.com/company/8212212","instagram":""},"social":["https://www.linkedin.com/company/8212212","https://www.facebook.com/Entera-Bio-%D7%9E%D7%97%D7%A7%D7%A8-%D7%9C%D7%AA%D7%A8%D7%95%D7%A4%D7%94-%D7%91%D7%95%D7%A0%D7%AA-%D7%A2%D7%A6%D7%9D-101763397878419"],"flattenedsociallinks":"https://www.linkedin.com/company/8212212|https://www.facebook.com/Entera-Bio-%D7%9E%D7%97%D7%A7%D7%A8-%D7%9C%D7%AA%D7%A8%D7%95%D7%A4%D7%94-%D7%91%D7%95%D7%A0%D7%AA-%D7%A2%D7%A6%D7%9D-101763397878419","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":null,"employees":"11-50","employees_exact":22,"patent":1,"raised":58900000,"stage":"Public","public_stage":"Public","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":["EnteraBio","Entrea Bio"],"about":"Entera Bio is a product-focused biotechnology company specializing in the oral delivery of large molecules and biologics.\nThe company currently conducts clinical trials utilizing its proprietary technology, which allows oral delivery of large molecules and biologics while enhancing their absorption in the gastrointestinal tract.\n\nEntera Bio's technology addresses the two major problems of oral drug delivery of large-molecule active pharmaceutical ingredients. Most large molecules cannot be administered orally as they are not readily absorbed by the gastrointestinal tract and are rapidly degraded by a myriad of enzymes and acids in the gastrointestinal tract. Entera's proprietary technologies act synergistically to transport and protect large molecules.\n\nThe company is developing first-in-class, daily tablet protein and peptide replacement therapies, designed for patients to live healthier and injection-free, as they manage their chronic diseases. \n\nEntera Bio is subsidiary of DNA Biomedical Solutions.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"","country":null,"address":{"israeli":[{"id":"fd1124ac-1c88-4c2d-9160-4fc8529b6898","city":"Jerusalem","type":null,"address":"Jerusalem, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":null},"headquarter_address":null,"district":"Jerusalem District","news":[{"id":"BFwTKjKxurFjpQJBqhaBIJ5aZHtEfrVs00DWCeoTinqPB77m4GCPbT","date":"Oct 23, 2025","link":"https://finance.yahoo.com/news/entera-bio-presents-positive-clinical-125000821.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical trial","round":null,"company":"Entera Bio Ltd.","layoffs":null,"summary":"Entera Bio Ltd. has reported promising clinical data from a Phase 2 trial of its oral anabolic treatment, EB613, at the 2025 North American Menopause Society Annual Meeting. The data demonstrates significant bone mineral density (BMD) gains in early postmenopausal women, highlighting EB613s potential as a first-in-class oral bone-building therapy. The company plans to initiate a global Phase 3 study following FDA concurrence in July 2025. This development could significantly improve patient access to osteoporosis treatment, addressing barriers associated with injectable therapies.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["BMD gains","EB613 efficacy","Phase 3 study","osteoporosis","oral therapy"],"date_of_event":"October 23, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","FDA approved/pending approval"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage  #FDA approved/pending approval","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"8zrBbHWZNvWsw77vMONoCSMIBPP5HPjPyH6oEmEQzwuOfY57U8l2Tg","news_summary":"Entera Bio Presents Positive New Clinical Data from EB613 Phase 2 Trial Demonstrating Significant Bone Density Improvements in Early Postmenopausal Women","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"eGRUTgkfSk2vRnz9mwKEWUYoPn3djxippmp3BfJBPkZDiXiS3fMlAT","date":"Oct 16, 2025","link":"https://finance.yahoo.com/news/entera-bio-present-clinical-data-124500930.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical trial","round":null,"company":"Entera Bio Ltd.","layoffs":null,"summary":"Entera Bio Ltd. is set to present new clinical data from its Phase 2 trial of EB613 at the North American Menopause Society 2025 Annual Meeting. The presentation will focus on bone mineral density outcomes in early postmenopausal women with low bone mass or osteoporosis. EB613 is being developed as the first oral anabolic tablet for osteoporosis, aiming to provide a more accessible treatment option compared to injectable therapies. The Phase 2 trial demonstrated positive results, meeting all biomarker and BMD endpoints without significant safety concerns. This development could potentially broaden access to anabolic therapies for the over 200 million women worldwide living with osteoporosis.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["osteoporosis","postmenopausal","anabolic therapy","oral tablet","clinical data"],"date_of_event":"October 16, 2025","product_stage":"Phase 2","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"not mentioned","structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"8W5MbXyWVBXbehPfnClcixqWHgjp778qnQO94326PwWhtCyshGAlxN","news_summary":"Entera Bio to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society (NAMS) Annual Meeting","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"aSqrlpUMWR7YY8NMNIK1ZFxWX8m1hjspaJ7Sjt6qbFor745P9W6C3S","date":"Oct 11, 2025","link":"https://finance.yahoo.com/news/individual-investors-entera-bio-ltd-123343402.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"ownership","round":null,"company":"Entera Bio Ltd.","layoffs":null,"summary":"Entera Bio Ltd. is significantly influenced by individual investors, who own 55% of the company, giving them substantial control over management and business strategy. The companys market capitalization increased by $34 million recently, benefiting these investors. Institutional investors also hold a notable portion of the company, suggesting credibility among professional investors. Hedge funds, owning 5.9% of the company, could potentially influence management decisions. Knoll Capital Management is the largest shareholder with 13% ownership. The ownership structure indicates that no single entity has a majority interest, allowing for diverse influence over the companys direction.","partners":null,"customers":null,"eventType":null,"investors":"Knoll Capital Management","confidence":9,"key_topics":["ownership","investors","market cap","institutional","hedge funds"],"date_of_event":"October 11th 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"asFYpjxUBDpt0WQnddFtQKfSl8Jrl9O7aQp68SerIseykMBfRfJlji","news_summary":"Individual investors are Entera Bio Ltd.'s (NASDAQ:ENTX) biggest owners and were rewarded after market cap rose by US$34m last week","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"uJkADHw9iSXVEVhU5ElHqd87gPbuO1KTJfzdvfa7BUYenRYoQIgsSB","date":"Sep 18, 2025","link":"https://finance.yahoo.com/news/entera-bio-unveils-promising-pk-124100416.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"pharmacokinetic data","round":null,"company":"Entera Bio Ltd.","layoffs":null,"summary":"Entera Bio Ltd. recently presented promising pharmacokinetic data for its oral GLP-2 analog therapy for short bowel syndrome (SBS) at the ESPEN Congress. The therapy, developed in collaboration with OPKO Health, aims to offer a more convenient alternative to existing treatments like Gattex, which require daily injections. The data demonstrated significant pharmacological advantages, including a longer plasma half-life and higher peak plasma concentrations compared to current therapies. While still in preclinical development, the therapys potential to address a market worth nearly $800 million annually could drive positive investor sentiment. The collaboration with OPKO Health is crucial for advancing this innovative treatment.","partners":"OPKO Health","customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["pharmacokinetics","oral therapy","SBS market","preclinical data","partnership"],"date_of_event":"September 2023","product_stage":"preclinical","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Partners"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"BAm4OkNStzYs8n7FuqqZy7qEuLOmY8RWTrrPmSXXqOr1PfvEOla1FY","news_summary":"Entera Bio Unveils Promising PK Data for First Oral GLP-2 Therapy","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"TVWsZ3zmAXhRhPt6RVWWR1vCQHpWMpcUvR83MYoiMH5lAod2NIfX1V","date":"Sep 15, 2025","link":"https://finance.yahoo.com/news/entera-bio-reports-positive-pk-130000236.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"preclinical data","round":null,"company":"Entera Bio Ltd.","layoffs":null,"summary":"Entera Bio Ltd. announced promising preclinical data for its oral GLP-2 analog, OPK-8801003, at the ESPEN Congress. The data showed a significantly longer biological half-life and higher peak plasma levels compared to the only approved GLP-2 therapy, Gattex®. This development could transform treatment for 30,000 short bowel syndrome patients who currently rely on daily injections. Enteras collaboration with OPKO Health combines OPKOs GLP-2 analog with Enteras N-Tab™ platform, aiming to offer a less invasive, personalized dosing option. The preclinical studies demonstrated robust oral bioavailability, sustained exposure, and a favorable safety profile.","partners":"OPKO Health, Inc.","customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["GLP-2 therapy","oral peptides","short bowel syndrome","pharmacokinetics","research collaboration"],"date_of_event":"September 15, 2025","product_stage":"preclinical","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Partners"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"not mentioned","structuredIssuesShow":"#Product Stage  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"KlK6VJmis7uG08jMsJ76GWOrYygHrBTo9LT7e244TUtPYxKRgSbBpf","news_summary":"Entera Bio Reports Positive PK Data for First-in-Class Oral GLP-2 Tablet Treatment for Patients with Short Bowel Syndrome at the 2025 ESPEN Congress","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"cNY9Q6MxAcYTbIpj0wQY6EMzNiCSapHf7MhaJDtfm31eTrAth32PDR","date":"Sep 8, 2025","link":"https://finance.yahoo.com/news/entera-bio-presents-positive-effects-123000337.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical trial","round":null,"company":"Entera Bio Ltd.","layoffs":null,"summary":"Entera Bio Ltd. announced promising results from its Phase 2 study of EB613, an oral treatment for osteoporosis, demonstrating significant improvements in bone health. The study showed that EB613 significantly increased trabecular and cortical bone parameters after six months, comparable to existing injectable treatments. The company plans to initiate a global Phase 3 study following FDA concurrence in July 2025. Entera Bio aims to address the treatment gap in osteoporosis care by providing an accessible oral alternative to injectable anabolic treatments. The data was presented at the ASBMR 2025 Annual Meeting, highlighting the potential of EB613 to rapidly strengthen bones and improve fracture resistance.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["osteoporosis","clinical trial","bone health","FDA concurrence","oral treatment"],"date_of_event":"September 8, 2025","product_stage":"Phase 2","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","FDA approved/pending approval"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage  #FDA approved/pending approval","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"iFj1JLZzCYCs2t0P0jkBYW6rMQRv1ESjNmqhMOi9T0CBEFxmd1l6Tm","news_summary":"Entera Bio Presents Positive Effects of EB613 on Both Trabecular and Cortical Bone in Postmenopausal Women with Osteoporosis at ASBMR 2025","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"gFcvuzQDU64X95ToAXPMlX7Gdk5GlvVfUGkzo9LIbxULDAhqpEkIyD","date":"Aug 28, 2025","link":"https://finance.yahoo.com/news/entera-bio-unveil-clinical-non-120000677.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"osteoporosis","round":null,"company":"Entera Bio Ltd.","layoffs":null,"summary":"Entera Bio Ltd., a leader in oral peptides and protein replacement therapies, is advancing its osteoporosis program with the EB613 oral tablet. The company is presenting Phase 2 study results at the ASBMR 2025 Annual Meeting, showing promising effects on bone density in postmenopausal women. Entera is planning a global Phase 3 registration study following FDA alignment. Additionally, Entera is exploring a GLP-2 tablet for short bowel syndrome, utilizing proprietary technology. The company will also present at the H.C. Wainwright 27th Annual Global Investment Conference, indicating ongoing investment interest. These developments highlight Enteras growth potential in the pharmaceutical sector.","partners":"OPKO Health","customers":null,"eventType":null,"investors":"H.C. Wainwright","confidence":10,"key_topics":["osteoporosis","oral peptides","clinical trials","bone health","investment"],"date_of_event":"August 28, 2025","product_stage":"Phase 2","investment_date":"September 5, 2025","acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Investment"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"not mentioned","structuredIssuesShow":"#Product Stage  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Kernr2ML391KHWnT9M9ddmLDYQ2R2JgsabaMb16cBBJoHfSTPWoEr2","news_summary":"Entera Bio to Unveil Clinical and Non-Clinical Data Across 3 Oral Peptide Programs at Upcoming September Conferences","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"LnGzriLLVZr1RrWkFtQNLE4gJMANltN645abjx2DIecA8L26RWEWBj","date":"Aug 11, 2025","link":"https://finance.yahoo.com/news/entera-bio-second-quarter-2025-103008023.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"financial-results","round":null,"company":"Entera Bio","layoffs":null,"summary":"Entera Bio reported a net loss of $2.66 million for the second quarter of 2025, which is a 24% increase in losses compared to the same period in 2024. The companys shares have decreased by 13% over the past week. The article highlights the financial challenges faced by Entera Bio, including a loss per share of $0.057. It also mentions a list of US stocks expected to pay a dividend yield of over 6% next year, although Entera Bio is not explicitly included in this list. The article provides a risk analysis, noting three warning signs for Entera Bio.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["net loss","share price","dividend yield","risk analysis","financial results"],"date_of_event":"August 11, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"PcMtfVPhGBbNpya9sZnAKNzCX2DsygXH8NqTKToAdaZPoztabNWvbe","news_summary":"Entera Bio Second Quarter 2025 Earnings: US$0.057 loss per share (vs US$0.058 loss in 2Q 2024)","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"9I90zehn4AxER5yRyNnN1SKDXhGd863xFhollT5BN24Hz6jbBkZ4tg","date":"Aug 8, 2025","link":"https://finance.yahoo.com/news/entera-bio-announces-second-quarter-200500050.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"FDA approval","round":null,"company":"Entera Bio Ltd.","layoffs":null,"summary":"Entera Bio Ltd. has received pivotal FDA agreement on the design of its Phase 3 trial for EB613, an oral anabolic treatment for osteoporosis, marking a significant regulatory milestone. The FDA has confirmed Bone Mineral Density (BMD) as the primary endpoint, streamlining the path to market. This decision supports Enteras strategic vision to address the unmet need for osteoporosis treatments. The company also reported strong financial results, with a cash position of $18.9 million, and highlighted its collaboration with OPKO, which is showing promising preclinical data. Entera plans to continue advancing its pipeline, including the next-gen EB613 expected to enter Phase 1 in November 2025.","partners":"OPKO","customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["FDA approval","osteoporosis","clinical trial","partnership","financial results"],"date_of_event":"August 08, 2025","product_stage":"Phase 3","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Partners"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"using","structuredIssuesShow":"#Product Stage  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"avmOKUYcxbKOTDkxSvzr6BNVMnxYCpLnGCXqdaqeXCtSrUBW3wUgcR","news_summary":"Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"iryqIY8o4H535Jt1KlK8ylOOpT2iw3V6lkq8GyU8GSnuBz3Es1olpQ","date":"Jul 31, 2025","link":"https://finance.yahoo.com/news/opko-health-reports-second-quarter-200500684.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical trials","round":null,"company":"OPKO Health, Inc.","layoffs":null,"summary":"OPKO Health, Inc. reported its business highlights and financial results for the second quarter of 2025. Key developments include Mercks advancement of a Phase 1 Epstein-Barr virus vaccine trial in collaboration with OPKO, and ModeXs progress in its immuno-oncology portfolio with several clinical candidates. OPKO also presented promising preclinical data on its novel GLP-1/glucagon receptor dual agonist, OPK-88006, at the American Diabetes Associations Scientific Sessions. Additionally, OPKO is developing an oral tablet formulation of OPK-88006 in collaboration with Entera, which will be presented at the ENDO 2025 annual meeting. These advancements indicate a positive growth trajectory for OPKO Health.","partners":["Merck","Entera"],"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["vaccine trial","immuno-oncology","antibody development","clinical data","collaboration"],"date_of_event":"July 31, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Partners"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"developing","structuredIssuesShow":"#Product Stage  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"OTbN5vjfNUSOdMbZuAEzjRlvuzbfWaBcSLVIB4wCPcArBrZcmMJ3Sv","news_summary":"OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"bNAhdNdQx7u0YXxsIG7IQMxl3TkkV7a87GfiGQSw8fLRtNjoakVxSQ","date":"Jul 28, 2025","link":"https://finance.yahoo.com/news/entera-bio-receives-fda-agreement-113000437.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"FDA approval","round":null,"company":"Entera Bio Ltd.","layoffs":null,"summary":"Entera Bio Ltd. announced that the FDA has agreed to support the NDA marketing application for their oral peptide treatment, EB613, with a single phase 3 study. This decision marks a significant milestone for the company, allowing them to advance their clinical development without waiting for the FDAs qualification of the Study to Advance Bone Mineral Density as a Regulatory Endpoint (SABRE). EB613 is being developed as the first oral, once-daily anabolic tablet treatment for osteoporosis, addressing a significant unmet medical need. The treatment has shown promising results in phase 2 trials, demonstrating efficacy in increasing bone mass and reducing fracture risk. This regulatory update is expected to accelerate the development and potential approval of EB613, offering a novel treatment option for osteoporosis patients.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["osteoporosis","FDA approval","clinical trial","oral treatment","bone health"],"date_of_event":"July 28, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","FDA approved/pending approval"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage  #FDA approved/pending approval","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"EtMBEZ5xrv5o6UOEO8yiKAGeGlosY8Avr3Y5jfCWxWKQUnL7ljcrOg","news_summary":"Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"oOWQdi6FA4juP20ozovZRMAaM02lAX3kbyozncgzUoGEt9c8PrIYTD","date":"Jul 23, 2025","link":"https://finance.yahoo.com/news/opko-health-opk-oral-glp-152512667.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"collaboration","round":null,"company":"OPKO Health, Inc.","layoffs":null,"summary":"OPKO Health, Inc., in collaboration with Entera Bio Ltd., announced the selection of their Oral GLP-2 Analog for a poster presentation at the 47th European Society for Clinical Nutrition & Metabolism Congress. This new therapy, which combines OPKOs long-acting GLP-2 agonist with Enteras N-Tab technology, aims to treat short bowel syndrome by providing an oral alternative to the currently approved injectable treatment, GATTEX. The oral format could improve patient compliance and comfort. OPKO Health is an international biopharmaceutical company developing and selling medicines, including treatments for kidney disease. The collaboration with Entera Bio is seen as a positive development for OPKO Health.","partners":["Entera Bio Ltd."],"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["biopharmaceutical","collaboration","therapy","presentation","investment"],"date_of_event":"July 8","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"using","structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"jLjo1vzlsKPEF96sm1JUJPfVlTgR5jgrBEevbYs51er9WDRTviyydY","news_summary":"OPKO Health’s (OPK) Oral GLP-2 Analog Selected for a Poster Presentation in Collaboration with Entera Bio (ENTX)","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"q2LazLVkAy5A5LAraJ811JwYaUwh9q4ftSuaMmZm5WDUTBghzX3fwQ","date":"Jul 16, 2025","link":"https://finance.yahoo.com/news/companies-entera-bio-nasdaq-entx-183107962.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"cash burn","round":null,"company":"Entera Bio","layoffs":null,"summary":"The article discusses Entera Bios financial situation, focusing on its cash burn and cash reserves. As of March 2025, Entera Bio had $13 million in cash and was debt-free, with a cash burn of $6.4 million over the past year, giving it a cash runway of two years. The company has reduced its cash burn by 16% over the last year, indicating a steady rate of business development. However, Entera Bios operating revenue remains low at $223,000, raising concerns about its ability to sustain growth without additional funding. The article suggests that shareholders should consider the companys potential to raise more cash in the future.","partners":null,"customers":null,"eventType":null,"investors":[],"confidence":9,"key_topics":["cash burn","cash runway","revenue","investment","growth"],"date_of_event":"March 2025","product_stage":"R&D","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"developing","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"tixrSvH67QhCfIiEOoi6Z0pQZTb575O51pH4b1Nk0UaWOgPDYwHght","news_summary":"Companies Like Entera Bio (NASDAQ:ENTX) Are In A Position To Invest In Growth","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"6oFguEMLUq7ei2tbqlA5Keyj2FwYZGV6fAMibT3UARapnbeJOZg09u","date":"Jul 8, 2025","link":"https://finance.yahoo.com/news/opko-health-entera-bio-announce-120000314.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"collaboration","round":null,"company":"OPKO Health, Inc.","layoffs":null,"summary":"OPKO Health, Inc. and Entera Bio Ltd. have announced that their joint abstract on a first-in-class oral GLP-2 analog for treating Short Bowel Syndrome (SBS) will be presented at the ESPEN Congress in September 2025. This collaboration combines OPKOs GLP-2 agonist with Enteras N-Tab™ technology, aiming to offer an oral alternative to the currently available injectable therapy, GATTEX®. The oral format could improve patient compliance and personalize treatment. Entera Bio is a clinical-stage company focused on developing oral peptide therapies, with several programs in the pipeline, including treatments for osteoporosis and hypoparathyroidism. The collaboration with OPKO is part of Enteras strategy to transform standard care for significant unmet medical needs.","partners":["Entera Bio Ltd."],"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["GLP-2","SBS","oral therapy","collaboration","clinical trials"],"date_of_event":"July 08, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Partners"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"uXFVhzYPBl9WYWTut1PKGsbUjWqTrBNVAgIAHq4gWFRTandNiyZHxY","news_summary":"OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"AXjhgrlzVpo5hXNjXXLjFSKEcg3ejPF0HjVUJlKtSwkxdENlmMOyiZ","date":"Jun 29, 2025","link":"https://finance.yahoo.com/news/opko-health-opk-present-opk-070329403.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"healthcare, partnership","round":null,"company":"OPKO Health, Inc.","layoffs":null,"summary":"OPKO Health, Inc., a diversified healthcare company, is set to present new data for its investigational oral OPK-88006 tablet treatment at ENDO 2025, in partnership with Entera Bio Ltd. The drug targets obesity, metabolic disorders, and fibrotic disorders, and is being developed as a novel dual agonist GLP-1/glucagon peptide. It will be available as a once-daily tablet and a weekly subcutaneous injection. The presentation will highlight the drugs pharmacologic effects and pharmacokinetic profile. This partnership and development are seen as growth-positive for OPKO Health, as it expands its pharmaceutical offerings in the metabolic therapy space.","partners":"Entera Bio Ltd.","customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["OPK-88006","ENDO 2025","partnership","metabolic disorders","pharmacologic effects"],"date_of_event":"June 25, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Partners"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"using","structuredIssuesShow":"#Product Stage  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"kGpxMi3jRwl3drOlrycgD9NUt3UhVkHu7bFIOck0bffstZTWsBbfYK","news_summary":"OPKO Health (OPK) to Present OPK-88006 Data at ENDO 2025","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"SN6izhxF4TxwvFW2C87z167LUIEOC3mC8brmJiLN9b6kP42qVTmFEF","date":"Jun 26, 2025","link":"https://finance.yahoo.com/news/entera-bio-data-eb613-effects-120000642.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"osteoporosis treatment","round":null,"company":"Entera Bio Ltd.","layoffs":null,"summary":"Entera Bio Ltd., a leader in developing oral peptides and protein replacement therapies, announced that its EB613 treatment for osteoporosis was selected for an oral presentation at the ASBMR 2025 Annual Meeting. EB613 is being developed as the first once-daily oral anabolic PTH(1-34) tablet for postmenopausal women with osteoporosis. The Phase 2 study showed promising results, with significant increases in bone mineral density and dual effects on bone formation and resorption. The presentation will further explore these findings using 3D-DXA analysis. This development positions Entera Bio as a potential leader in addressing the treatment gap in osteoporosis care.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["osteoporosis","oral treatment","bone health","clinical trial","womens health"],"date_of_event":"June 26, 2025","product_stage":"Phase 2","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"using","structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"eHKXYIEKkkxpxQ1x6CKsMttxKnVgfdD9Q4Hqlii9JenZRt789koVf5","news_summary":"Entera Bio Data for EB613 Effects on Trabecular and Cortical Bone in Post-Menopausal Women with Osteoporosis Selected for Oral Presentation at ASBMR 2025 Annual Meeting","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"2edGhBOmjG14QctdtWHsRriRzwNhmxXYSWxwajCM7rVKhwJhQWB2wi","date":"Jun 25, 2025","link":"https://finance.yahoo.com/news/opko-health-entera-bio-abstract-120000844.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"collaboration","round":null,"company":"Entera Bio Ltd.","layoffs":null,"summary":"Entera Bio Ltd. and OPKO Health, Inc. have announced new data for their investigational oral OPK-88006 tablet treatment, which will be presented at the ENDO 2025 annual meeting. The companies are collaborating on a novel dual agonist GLP-1/glucagon peptide treatment for obesity and metabolic disorders, available as both a tablet and a weekly injection. Entera Bio is leveraging its proprietary N-Tab™ technology in this collaboration. They plan to file an Investigational New Drug application with the FDA later this year and are preparing for Phase 1 clinical studies. Entera Bio is a clinical-stage company focused on developing oral peptide therapies for unmet medical needs, with several programs in development, including treatments for osteoporosis and hypoparathyroidism.","partners":"OPKO Health, Inc.","customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["collaboration","clinical trials","FDA application","metabolic disorders","oral peptides"],"date_of_event":"June 25, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Partners"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"pSPtzhIKGNtkQ6FcYibq2Xac3VpPU6cIaFCdMkO7TIeDJF5PS6OVuB","news_summary":"OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"7RWLPnOBITfdSJRziCSOyByk1rDBrYmqFwYtC7IR8KKpQgZCUsOVet","date":"Jun 24, 2025","link":"https://finance.yahoo.com/news/piper-sandler-reiterates-buy-rating-195208621.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"collaboration","round":null,"company":"Opko Health Inc.","layoffs":null,"summary":"Opko Health Inc. has been highlighted as a promising long-term penny stock. The company recently announced the sale of its BioReference laboratory testing businesses for up to $225 million, including a $192.5 million payout at closing and a potential $32.5 million performance-based earnout. Additionally, Opko Health has entered a collaboration with Entera Bio to advance oral GLP-1/glucagon tablet candidates for metabolic disorders and obesity. The company is also progressing with its ModeX immuno-oncology and immunology portfolio, with four potential clinical candidates in the pipeline. Despite these developments, some analysts suggest that AI stocks may offer greater upside potential.","partners":"Entera Bio","customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["acquisition","collaboration","investment","biopharmaceutical","diagnostics"],"date_of_event":"May 2, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":"BioReference laboratory testing businesses","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Acquisition","Partners"],"acquisition_amount":"$225 million","FDA approved/pending approval":"pending approval","AI technology developing/using":"using","structuredIssuesShow":"#Acquisition  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"6Ge4uEW6O4htZdk3NmcV9snkO1jlE9kgGvtjjkYt6H5qbATl8mc426","news_summary":"Piper Sandler Reiterates a Buy Rating on Opko Health (OPK) With a $3 PT","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"LU3BhYaKKaCv6u8Lsw661juBkJqj3mkjuteoPIEbWyqsXeYlTnsK27","date":"May 9, 2025","link":"https://finance.yahoo.com/news/entera-bio-announces-first-quarter-200500091.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"osteoporosis treatment","round":null,"company":"Entera Bio Ltd.","layoffs":null,"summary":"Entera Bio Ltd. reported financial results and business updates for Q1 2025, highlighting progress in developing oral peptide therapies. The company extended its cash runway to late 2026 through direct investment from OPKO Health Inc., a strategic partner. Entera is advancing its EB613 osteoporosis treatment, with plans for a Phase 1 study in H2 2025. The company is also co-developing Oral OPK-88006 for metabolic diseases with OPKO. Recent management appointments aim to strengthen strategic execution. Entera supports the SABRE initiative, advocating for FDA regulatory reform to use bone mineral density as a surrogate endpoint for osteoporosis drug approval, potentially accelerating innovation in this field.","partners":"OPKO Health Inc.","customers":null,"eventType":null,"investors":"OPKO Health Inc.","confidence":9,"key_topics":["osteoporosis","investment","FDA approval","clinical trials","partnerships"],"date_of_event":"May 09, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment","Partners","Management Changes","Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"developing","structuredIssuesShow":"#Investment  #Partners  #Management Changes  #Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"jidZSxnBBaixCF5AgfUeVuO0w9W7hdmtuM8OCSHKnAGav9CvpQOYEe","news_summary":"Entera Bio Announces First Quarter 2025 Financial Results and Business Updates","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"g6Ci2NZD6FMS7ycrDERoZjSKlg26NXcVqHC3AxgLF5wEgMMf4PKaSA","date":"Apr 15, 2025","link":"https://finance.yahoo.com/news/entera-bio-eb613-demonstrates-early-123000339.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical trial","round":null,"company":"Entera Bio Ltd.","layoffs":null,"summary":"Entera Bio Ltd. announced promising results from a Phase 2 study of their oral anabolic therapy, EB613, at the 2025 World Congress on Osteoporosis. The study involved 161 postmenopausal women with osteoporosis, showing that EB613 significantly increased bone mineral density (BMD) compared to placebo. The findings suggest that EB613, the first once-daily oral anabolic PTH(1-34) tablet, could rapidly strengthen bones and improve fracture resistance. The company plans to further investigate the safety and efficacy of EB613 in a Phase 3 trial. The results are consistent with those of subcutaneous teriparatide, indicating a potential breakthrough for non-injectable osteoporosis treatments.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["osteoporosis","clinical trial","bone health","oral therapy","postmenopausal"],"date_of_event":"April 15, 2025","product_stage":"Phase 2","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"not mentioned","structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"ynx6ehybR9ocUqOw6KmLCbucUZMgbXcVkixNnFfEtKs1DGghVOWgwH","news_summary":"Entera Bio’s EB613 Demonstrates Early Impact on Both Trabecular and Cortical Bone Compartments with 6 Months of Treatment in Post-Menopausal Women with Osteoporosis - Highlighted as Oral Presentation at WCO-IOF ESCEO","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"T1HbaRKtOyJ5DpqY17ENLfQsYg4nZmHKFmBNGL2FlMnXOlZZK4OOrr","date":"Mar 28, 2025","link":"https://finance.yahoo.com/news/entera-bio-announces-full-2024-200500997.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"osteoporosis treatment","round":null,"company":"Entera Bio Ltd.","layoffs":null,"summary":"Entera Bio Ltd., a leader in developing oral peptides and protein replacement therapies, reported significant advancements in 2024. The company progressed its oral peptide programs, including EB613 for osteoporosis, and increased stockholder value. Entera is preparing for a pivotal Phase 3 study of EB613, pending FDA review of the SABRE initiative, which could redefine regulatory endpoints for osteoporosis treatments. The company has partnered with OPKO Health, Inc. to expand its N-Tab™ platform. Entera aims to address the treatment gap for osteoporosis, a condition affecting millions of women globally, with its innovative oral therapy. The company plans to continue its growth and execution strategy in 2025.","partners":"OPKO Health, Inc.","customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["osteoporosis","oral peptides","clinical trials","FDA review","partnerships"],"date_of_event":"March 28, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Partners","Expand"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage  #Partners  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"5bHjurhfBIO80DSZrpCsdqa6EU7pcbDN371tRu0ZGMFBm4wUDPOS4u","news_summary":"Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"h0z0QeLuZWvAkXxTaVfbHVHT2MLjJ2NJZhnk5X8JH5NV0twG8nlAVN","date":"Mar 18, 2025","link":"https://www.pharmaceutical-technology.com/news/opko-entera-oral-treatment-metabolic-disorders/","source":"www.pharmaceutical-technology.com","visible":1,"analysis":{"tags":"partnership","round":null,"company":"Opko Health","layoffs":null,"summary":"Opko Health and Entera Bio have entered into a partnership and license agreement to develop the first oral dual agonist glucagon-like peptide-1 (GLP-1)/glucagon for treating metabolic, fibrotic, and obesity disorders. Opko will hold a 60% ownership interest, while Entera will hold 40%. Opko has invested in Entera by purchasing 3.69 million ordinary shares at $2.17 each to fund the development costs through Phase I. Entera may choose to continue funding to maintain its stake or opt out, retaining a 15% interest. The companies plan to submit an investigational new drug application to the FDA in 2025.","partners":["Entera Bio"],"customers":null,"eventType":null,"investors":"Opko Health","confidence":10,"key_topics":["partnership","investment","obesity","oral treatment","drug development"],"date_of_event":"March 18, 2025","product_stage":"Phase I","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"3.69 million shares at $2.17 each","structured_issues":["Partners","Investment","Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"using","structuredIssuesShow":"#Partners  #Investment  #Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"oOqzRbwIXaCK0rplgfxZ5TrKC9mawDMjJPtW8N8DNR0LC48I8rmDXG","news_summary":"Opko and Entera focus on oral care for obesity and metabolic disorders","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"zz9PiusrK8es1NO2NiI7LTtSSVXEvDaBHxojAz4YMcmkb71U95CsvL","date":"Mar 17, 2025","link":"https://finance.yahoo.com/news/opko-health-entera-bio-enter-120000016.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"collaboration","round":null,"company":"OPKO Health, Inc.","layoffs":null,"summary":"OPKO Health, Inc. and Entera Bio Ltd. have entered into a collaboration and license agreement to develop an oral dual agonist GLP-1/glucagon peptide for treating obesity, metabolic, and fibrotic disorders. The program combines OPKOs oxyntomodulin analog with Enteras N-Tab™ technology. The companies plan to file an Investigational New Drug application with the FDA later this year. OPKO will hold a 60% ownership interest and Entera 40%, with respective responsibilities for development costs. OPKO also purchased shares of Entera to fund its share of development costs. The collaboration aims to provide new treatment options for patients. The program is currently in the clinical trial stage.","partners":["Entera Bio Ltd."],"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["collaboration","oral peptides","obesity treatment","FDA application","ownership interests"],"date_of_event":"March 17, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Investment","Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Partners  #Investment  #Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"UMxTryC9JjBEpf17eakhgEkpPdm5cFjcWFrVNgIFQL71YY6ElI28mk","news_summary":"OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"T0RrNQqWrrwY8WfAlD033sCbeiCmsgHsXY3uysY4vC01DDCDGveyMv","date":"Feb 24, 2025","link":"https://finance.yahoo.com/news/entera-bio-participate-upcoming-events-133000229.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical development","round":null,"company":"Entera Bio Ltd.","layoffs":null,"summary":"Entera Bio Ltd., a clinical-stage company, is advancing its development of oral peptide and protein replacement therapies. The company is preparing to initiate a Phase 3 registrational study for its most advanced product candidate, EB613, an oral tablet treatment for osteoporosis. Entera is also developing other oral peptide therapies, including EB612 for hypoparathyroidism and a GLP-2 peptide for malabsorption conditions, in collaboration with OPKO Health. The companys participation in upcoming global healthcare conferences highlights its commitment to addressing unmet medical needs with innovative oral therapies. Enteras proprietary technology platform, N-Tab™, supports its pipeline of first-in-class oral peptide programs.","partners":"OPKO Health","customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["oral therapies","osteoporosis","clinical trials","FDA approval","partnerships"],"date_of_event":"February 24, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Partners"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"not mentioned","structuredIssuesShow":"#Product Stage  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"GGr682Z1DnnKmDmIsnMfumdotivEq2xyjNVLFq8kHyZdGRk4qFCakG","news_summary":"Entera Bio to Participate in Upcoming Events","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"oyMkmCExy8TIq3Sx0Eya8fAQ51tPtqJHXcKuByMqR7jEpFBkvN8W64","date":"Feb 19, 2025","link":"https://finance.yahoo.com/news/effects-eb613-tablets-oral-pth-130000589.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"osteoporosis treatment","round":null,"company":"Entera Bio Ltd.","layoffs":null,"summary":"Entera Bio Ltd., a leader in oral peptide and protein replacement therapies, announced that its abstracts related to EB613 have been accepted for presentation at the World Congress on Osteoporosis. EB613 is being developed as a once-daily oral anabolic PTH(1-34) tablet for high-risk post-menopausal women with osteoporosis. The Phase 2 study demonstrated significant increases in bone mineral density and bone formation. The presentations will occur at the WCO-IOF-ESCEO congress in Rome in April 2025. The company aims to address the treatment gap in osteoporosis care with this innovative oral solution, providing an alternative to injectable treatments.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["osteoporosis","EB613","oral treatment","bone health","clinical study"],"date_of_event":"February 19, 2025","product_stage":"Phase 2","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"not mentioned","structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"xGvPwGCqaQF5yPneHzBo9MKdBd8Tb9L7DmRmrwQvsVpw4uSNbpgH0Z","news_summary":"EFFECTS OF EB613 TABLETS [ORAL PTH(1-34)] ON TRABECULAR AND CORTICAL BONE USING 3D-DXA: POST-HOC RESULTS FROM PHASE 2 STUDY Accepted for Oral Presentation at World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"3MNW73jIXVKahw4cPjxQckNO0CX83rjjFysxXWWOnRLC417qQXxE5c","date":"Feb 7, 2025","link":"https://finance.yahoo.com/news/us-penny-stocks-3-picks-171106436.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"financial health","round":null,"company":"Entera Bio Ltd.","layoffs":null,"summary":"Entera Bio Ltd. is a clinical-stage biotech company focused on developing oral peptide or protein replacement therapies for unmet medical needs. With a market cap of $88.4 million, the company is pre-revenue and faces potential liquidity challenges due to having less than a year of cash runway and no debt. Despite reducing losses by 2.8% annually over the past five years, Entera Bio remains unprofitable and is not expected to achieve profitability in the next three years. The companys experienced management and board provide some stability amid high share price volatility and significant net losses.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["penny stocks","market cap","financial health","clinical stage","liquidity challenges"],"date_of_event":"February 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":"$88.4M","impact_on_company":"growth-negative","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"LXGBAXqMYET7JDsDEwbTqVKnPSW6y5fzYCMusXNnE5amIifxPb2JYN","news_summary":"US Penny Stocks: 3 Picks With Market Caps Over $60M","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"UYqxmblFthRZhE4n71M7Fa8LVQ5E9F5p3pamEL4vYtxlufLgGTTHdo","date":"Feb 6, 2025","link":"https://finance.yahoo.com/news/entera-bio-nasdaq-entx-good-153946328.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"cash burn","round":null,"company":"Entera Bio","layoffs":null,"summary":"Entera Bio, an unprofitable company, has seen a significant increase in its share price by 225% over the last year. However, the company is experiencing a high cash burn rate, spending $8.0 million annually with only $6.9 million in cash reserves as of September 2024. This gives it a cash runway of approximately 10 months, indicating an urgent need to reduce cash burn or raise additional funds. Despite a small revenue of $99,000 in the past year, the company has increased its cash burn by 19%, suggesting increased investment in future growth. Entera Bio may need to consider raising capital through debt or equity to sustain its operations.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["cash burn","cash reserves","share price","investment","revenue"],"date_of_event":"February 6th 2025","product_stage":"R&D","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"developing","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"lfFcWrqkQBMoS0vaSvw8QJ07tTSxtEBedLAzQvEDpOTVuaJDoddJz1","news_summary":"Is Entera Bio (NASDAQ:ENTX) In A Good Position To Deliver On Growth Plans?","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"MgKHMacUldvpG3J92D1e1QdRFWnyZ47vQCG1D8ZcSqGeg0mllXXFSg","date":"Jan 27, 2025","link":"https://finance.yahoo.com/news/entera-bio-present-oppenheimer-35th-130000409.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical development","round":null,"company":"Entera Bio Ltd.","layoffs":null,"summary":"Entera Bio Ltd., a clinical-stage company specializing in orally delivered peptides and therapeutic proteins, announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference in February 2025. The company is advancing its pipeline, including EB613, an oral osteoanabolic tablet for osteoporosis, which has shown promising results in Phase 2 trials. Entera plans to initiate a Phase 3 study for EB613 in the second half of 2025. Additionally, Entera is developing EB612 for hypoparathyroidism and collaborating with OPKO Health on oral peptide therapies for obesity and gastrointestinal conditions. The companys innovative approach and strategic partnerships position it for growth in addressing unmet medical needs.","partners":"OPKO Health","customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["oral peptides","clinical trials","osteoporosis","hypoparathyroidism","partnerships"],"date_of_event":"January 27, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Partners"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"iokEIyDntdhKhcLC5qoGk2sp7S32n8jjnNpfRwxf3nYJ1MI1MtJSf7","news_summary":"Entera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"JVpkOjCalPfvIDWmpiyXfT2cZLK6JPos8V07T4Aq1wL1WEFoJibNRx","date":"Nov 8, 2024","link":"https://finance.yahoo.com/news/entera-bio-reports-q3-2024-210500541.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"osteoporosis treatment","company":"Entera Bio Ltd.","layoffs":null,"summary":"Entera Bio Ltd., a company specializing in oral peptides and therapeutic proteins, reported its financial results and business updates for Q3 2024. The company highlighted its pivotal clinical asset, EB613, an oral PTH(1-34) tablet for post-menopausal women with osteoporosis. Enteras N-Tab™ platform has shown consistent performance across various programs. The company anticipates a significant FDA ruling on osteoporosis drug regulatory endpoints in January 2025, which could benefit EB613. Entera aims to address the treatment gap in osteoporosis, a major womens health issue. Recent pharmacological data for EB613 was presented at the ASBMR 2024 Annual Meeting, indicating progress in their clinical trials.","partners":null,"customers":null,"investors":null,"confidence":10,"key_topics":["osteoporosis","oral peptides","clinical trials","regulatory guidelines","advisory board"],"date_of_event":"November 08, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"AyScQSSv0wzuG0iEqtEIwYBKAhzqhiCEFqvTBg6K5NCWG6Iwcfj39j","news_summary":"Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"37Rfqfa3j0LenLMmbUGECdcGHPm4AWNY7o2CXYYcDHCsx4mIf8PANr","date":"Nov 8, 2024","link":"https://finance.yahoo.com/news/entera-bio-ltd-entx-reports-221502982.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"earnings report","company":"Entera Bio Ltd.","layoffs":null,"summary":"Entera Bio Ltd. reported a quarterly loss of $0.08 per share, which was worse than the Zacks Consensus Estimate of a $0.05 loss, resulting in an earnings surprise of -60%. Despite this, the company posted revenues of $0.04 million, surpassing the consensus estimate by 5%. Entera Bios stock has increased by 191.7% since the beginning of the year, outperforming the S&P 500s gain of 25.2%. The companys future stock performance will depend on managements commentary and earnings outlook. Currently, the stock holds a Zacks Rank #3 (Hold), indicating it is expected to perform in line with the market. The consensus EPS estimate for the coming quarter is -$0.06 with $0.04 million in revenues.","partners":null,"customers":null,"investors":null,"confidence":10,"key_topics":["earnings","revenue","stock performance","estimates","Zacks Rank"],"date_of_event":"September 2024","valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"whoF6zvNdrRa99q4TpOe12FCgfFyTYQv2vxEgFhia6FKAe59QeNjuN","news_summary":"Entera Bio Ltd. (ENTX) Reports Q3 Loss, Tops Revenue Estimates","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"gn8jdTM2CbNIxze9dbcuu9wBPe2AZn7o5zEHaPy7eBMCfgM1MSH6Bp","date":"Oct 4, 2024","link":"https://finance.yahoo.com/news/medical-stocks-lagging-argenx-argx-134009618.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"stock performance","company":"argenex SE","layoffs":null,"summary":"The article discusses the performance of argenex SE (ARGX) within the Medical sector, highlighting its strong year-to-date performance. ARGX has gained about 42.7% this year, significantly outperforming the average return of 7.2% for Medical companies. The company holds a Zacks Rank of #1 (Strong Buy), indicating positive analyst sentiment and an improved earnings outlook. The Zacks Consensus Estimate for ARGXs full-year earnings has increased by 87.4% over the past three months. The article also mentions Entera Bio Ltd. (ENTX), another Medical stock with a high return of 206.7% this year. Both companies are part of the Medical - Biomedical and Genetics industry, with ARGX performing better than its industry peers.","partners":[],"customers":[],"investors":[],"confidence":9,"key_topics":["Medical sector","Zacks Rank","earnings estimates","stock performance","industry comparison"],"date_of_event":"Not specified","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"4Roo5ifU1iHsgzyP8jtqhLJDGh9oRB0jDbBbaTrO6wKeRUxbPOR7NL","news_summary":"Are Medical Stocks Lagging  Argenx (ARGX) This Year?","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"NjTCUbGn6nLvwdrq7I1ija33uDViKo3UJM5Q9xUvF8X03kgziERpNz","date":"Sep 26, 2024","link":"https://finance.yahoo.com/news/entx-opk-stock-may-gain-165100047.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"collaborative research","company":"Entera Bio Ltd. and OPKO Health, Inc.","layoffs":null,"summary":"Entera Bio Ltd. (ENTX) and OPKO Health, Inc. (OPK) announced positive topline pharmacokinetic/pharmacodynamic (PK/PD) results from their collaborative research on a long-acting oxyntomodulin (OXM) analog. This program aims to develop the first oral dual agonist GLP-1/glucagon peptide for treating obesity and metabolic disorders. Despite the positive results, ENTX shares fell by 1.5%, while OPK shares remained flat. The global weight management market is projected to grow significantly, which could benefit both companies. The research demonstrated significant systemic exposure and favorable pharmacokinetic profiles in animal models. The companies plan to present these findings at a future clinical meeting.","partners":["OPKO Health, Inc."],"customers":[],"investors":[],"confidence":9,"key_topics":["PK/PD results","weight management","oral treatment","obesity","market performance"],"date_of_event":"Wednesday (specific date not provided)","valuation_amount":"ENTX: $70.14 million, OPK: $1.03 billion","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"bBitJI67n4wcR0hep9e4y4c3fLu4v8C7ryx1x3c5fx6rYfwTkQcLix","news_summary":"ENTX & OPK Stock May Gain Following Positive PK/PD Research Data","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"20HVBWQebx6BPw8s5HKTsm82weLUNm4nru0J5swfUsPjWIOgqQMaSN","date":"Sep 25, 2024","link":"https://finance.yahoo.com/news/entera-bio-opko-health-pk-123000390.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"collaboration, research","company":"Entera Bio Ltd.","layoffs":null,"summary":"Entera Bio Ltd. and OPKO Health, Inc. announced positive topline results from their collaborative research on an oral dual agonist GLP-1/glucagon peptide for treating obesity and metabolic disorders. The study demonstrated significant systemic exposure and favorable pharmacokinetic profiles in rodent and pig models. The collaboration aims to develop the first oral oxyntomodulin (OXM) analog, leveraging Enteras N-Tab™ technology and OPKOs OXM analog. The companies plan to present these findings at an upcoming clinical conference. Enteras CEO expressed satisfaction with the progress, indicating continued efforts towards IND-enabling studies.","partners":["OPKO Health, Inc."],"customers":[],"investors":[],"confidence":10,"key_topics":["collaboration","research","obesity","peptides","treatment"],"date_of_event":"September 25, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"sxuojZGAvzj8o4rleY8e3cdnY22FJ8kpNUkWGKvdE5JspofIykoCq9","news_summary":"Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"qAS9spwsYzo4pb6gaTBniXuOE7kYRIgyuQJV2zOExAVTMZVUOsJuo6","date":"Sep 18, 2024","link":"https://finance.yahoo.com/news/entera-bio-entx-stock-outpacing-134013014.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"performance","company":"Entera Bio Ltd.","layoffs":null,"summary":"Entera Bio Ltd. (ENTX) has shown strong performance in the Medical sector, outperforming its peers with a year-to-date return of 253.3%. The company holds a Zacks Rank of #2 (Buy), indicating a positive earnings outlook. Over the past three months, the Zacks Consensus Estimate for ENTXs full-year earnings has increased by 8%, reflecting improved analyst sentiment. The Medical sector, in general, has returned an average of 10.9% year-to-date. Another strong performer in the sector is argenex SE (ARGX), with a year-to-date return of 37.3% and a similar Zacks Rank of #2 (Buy). Both companies belong to the Medical - Biomedical and Genetics industry, which has gained an average of 2.3% this year.","partners":null,"customers":null,"investors":[],"confidence":10,"key_topics":["performance","earnings","sector","rank","outlook"],"date_of_event":"2023","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"nUPi7MzsMN0CkgHWXbyZopy7w1WU8vkgwpXl2fYB9K2BiQ0geWxlPg","news_summary":"Is Entera Bio (ENTX) Stock Outpacing Its Medical Peers This Year?","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"6SJYRKQmu0JpIp3Lpb7RMCzG47weqoLDCW9x0Hvl2k4ygXwA3SAXHr","date":"Sep 2, 2024","link":"https://finance.yahoo.com/news/entera-bio-entx-outperforming-other-134011103.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"stock performance","company":"Entera Bio Ltd.","layoffs":null,"summary":"Entera Bio Ltd. (ENTX) has shown strong performance in the Medical sector, outperforming its peers with a year-to-date return of 178.3%, compared to the sectors average of 12.7%. The company holds a Zacks Rank of #2 (Buy), indicating positive analyst sentiment and an improving earnings outlook, with the Zacks Consensus Estimate for full-year earnings moving 8% higher in the past quarter. Another notable performer in the sector is Akebia Therapeutics (AKBA), which has also outperformed with a 25% year-to-date return and a Zacks Rank of #2 (Buy). Investors are advised to keep an eye on these stocks for continued solid performance.","partners":null,"customers":null,"investors":[],"confidence":9,"key_topics":["Medical stocks","Zacks Rank","Earnings estimates","Year-to-date performance","Analyst sentiment"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"RLcGv6mZqK0wgMjzBB0WYoOMZpcFwr6xPxri22NnRdrtkdSQTQvZWo","news_summary":"Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"tEBZioXLKs95qbeb55e5zSPwz73U1pxaBsVnbnO3LtAj64Kc3QxRO9","date":"Aug 30, 2024","link":"https://finance.yahoo.com/news/were-keeping-eye-entera-bios-133615331.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"cash burn","company":"Entera Bio","layoffs":null,"summary":"Entera Bio, listed on NASDAQ as ENTX, has seen a significant increase in its stock price, up 139% over the past year. Despite being unprofitable, the company has managed its cash burn effectively, reducing it by 8.9% over the last year. As of June 2024, Entera Bio had $9.1 million in cash reserves and a cash burn rate of $7.3 million annually, giving it a cash runway of approximately 15 months. The company has a market capitalization of $60 million, and it is likely to raise more cash through issuing new shares or taking on debt. The article suggests that while there are risks associated with cash-burning companies, Entera Bios situation appears manageable.","partners":null,"customers":null,"investors":[],"confidence":10,"key_topics":["cash burn","cash reserves","market cap","fundraising","share price"],"date_of_event":"June 2024","valuation_amount":"60 million USD","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"vUSVVfNbFQZ7V4KTkMPO8EtmLsx6ivfSf3mU83WYTqXytiZoRDoU6S","news_summary":"We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"lqqTGvpY4b4SOmAjvqiJdeXJaPoDHC2kNr3twJgGo799QfEPEb6BUZ","date":"Aug 20, 2024","link":"https://finance.yahoo.com/news/entera-bio-participate-upcoming-investor-120000518.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Investment, Management Changes","company":"Entera Bio Ltd.","layoffs":"Not mentioned","summary":"Entera Bio Ltd., a leader in the development of orally delivered peptides and small therapeutic proteins, announced that its management will be participating in various investor and scientific conferences. The company is focused on developing oral peptide or protein replacement therapies for significant unmet medical needs. Its pipeline includes five differentiated, first-in-class oral peptide programs, expected to enter the clinic (Phase 1 to Phase 3) by 2025. The companys most advanced product candidate, EB613, is being developed for post-menopausal women with low BMD and high-risk osteoporosis. The company is also developing the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity; and first oral GLP-2 peptide tablet as an injection-free alternative for patients suffering from rare malabsorption conditions such as short bowel syndrome in collaboration with OPKO Health.","partners":"OPKO Health","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Investor Conference","Scientific Conference","Clinical Trials","Product Development","Regulatory Approval"],"date_of_event":"August 20, 2024","valuation_amount":"Not mentioned","impact_on_company":"Growth-Positive","investment_amount":"Not mentioned","structured_issues":"Investment, Management Changes","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment, Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"OsSZEhmvuY5dSw2futORivy0KjhWfYXdPYMVsPllE41UadUCHnEmX1","news_summary":"Entera Bio to Participate in Upcoming Investor and Scientific Conferences","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"IkTzTdrq6Kwolztu2DWwhq8za3fTHFaGeOOwcNXATFQXxwvYT9Vhho","date":"Aug 15, 2024","link":"https://finance.yahoo.com/news/know-entera-bio-entx-rating-160033739.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Stock Upgrade, Earnings Estimates","company":"Entera Bio Ltd.","layoffs":"N/A","summary":"Entera Bio Ltd. has been upgraded to a Zacks Rank #2 (Buy), reflecting an upward trend in earnings estimates. The Zacks rating system tracks EPS estimates for the current and following years from sell-side analysts, and is a powerful factor influencing near-term stock price movements. The rating upgrade for Entera Bio is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price. For the fiscal year ending December 2024, Entera Bio is expected to earn -$0.23 per share, a change of 25.8% from the year-ago reported number.","partners":"N/A","customers":"N/A","investors":"Zacks Investment Research","confidence":9,"key_topics":["Zacks Rank","Earnings Estimate Revisions","Stock Price","Investment Research","Future Earnings Potential"],"date_of_event":"N/A","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Investment"],"acquisition_amount":"N/A","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"n2JRaL9t2Tv7KCzynmiKfkDctevVfVArMkMo438Wn6lBVHZjKREqUh","news_summary":"All You Need to Know About Entera Bio (ENTX) Rating Upgrade to Buy","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ocbGWPSkJDkwd6gZxh2TFMm6yPOR76QKQR4w5t0wh2XRBxs8MrOIf7","date":"Aug 9, 2024","link":"https://finance.yahoo.com/news/entera-bio-reports-q2-2024-200500962.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"financial results, clinical development","company":"Entera Bio Ltd.","layoffs":"N/A","summary":"Entera Bio Ltd., a leader in the development of orally delivered peptides and small therapeutic proteins, reported financial results and key business updates for Q2 2024. The company is preparing for FDAs potential landmark ruling on the ASBMR-FNIH SABRE regulatory endpoint for osteoporosis drugs. Entera welcomed Dr. Rachel Wagman as Key Clinical Advisor to lead EB613 clinical development. The company continues to collaborate with a third party on the development of another PTH replacement treatment for hypoparathyroidism. As of June 30, 2024, Entera had cash and cash equivalents of $9.1 million.","partners":"OPKO Health, Inc.","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["financial results","clinical development","FDA ruling","osteoporosis drugs","collaboration"],"date_of_event":"Aug. 09, 2024","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Investment","Management Changes","Expand"],"acquisition_amount":"N/A","structuredIssuesShow":"#Investment  #Management Changes  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"kheIDiluPaU2ef896UIt0VxkiyANtSx8rPMMhi6MMJoIlyBTHZqFhM","news_summary":"Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"2hYtWOSHyAsgUwWbIkfswWOrcAGDf3t3z4fZqKQALYFOsSktQ0HLp1","date":"Aug 1, 2024","link":"https://finance.yahoo.com/news/entera-eb613-first-once-daily-123000232.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Pharmaceutical Research","company":"Entera Bio Ltd.","layoffs":"Not mentioned","summary":"Entera Bio Ltd. has announced that new comparative pharmacological data for its investigational agent EB613 vs. Forteo® was selected for presentation at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting. EB613 is being developed as the first once-daily oral anabolic (bone forming) PTH(1-34) mini tablet therapy for post-menopausal women with high risk osteoporosis. The company is preparing to initiate a Phase 3 registrational study for EB613 pursuant to the FDA’s qualification of a quantitative BMD endpoint which is expected to occur by January 2025.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["EB613","Osteoporosis","Oral Anabolic Treatment","ASBMR 2024","Clinical Trials"],"date_of_event":"Aug. 01, 2024","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Investment","Expand"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"AuCwChq6JRNJdCFnuhDLE1F0wKpESXzqIJDJr1MBaTSu9B1Xe7nNBQ","news_summary":"Entera’s EB613, the First Once Daily PTH(1-34) Tablet Treatment Dedicated to Post-Menopausal Women with High Risk Osteoporosis Abstract Selected for Presentation at the ASBMR 2024 Annual Meeting - Key SABRE Update Also Expected","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"PZClqjvuZLD4vdf5ruFtn0TZN5AxvMrmnOpF73PlciKbOZXcfXzTBm","date":"Jul 23, 2024","link":"https://finance.yahoo.com/news/3-meme-stocks-buy-hold-102800257.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"meme stocks, investment","company":"Cronos, Entera Bio, Bitfarms","layoffs":"Not mentioned","summary":"The article discusses the potential of three meme stocks - Cronos, Entera Bio, and Bitfarms - to deliver significant returns in the next three years. Cronos, a cannabis company, is expected to benefit from increasingly friendly regulations in the sector and has a strong cash buffer for investments and potential acquisitions. Entera Bio, a clinical-stage biotech company, has a promising product candidate for the treatment of high-risk, post-menopausal osteoporosis. Bitfarms, a Bitcoin miner, is well-positioned for aggressive expansion with a zero-debt balance sheet and strong liquidity.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":8,"key_topics":"meme stocks, investment, growth, expansion, revenue","date_of_event":"Not mentioned","valuation_amount":"Cronos - $907 million","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":"Investment, Expand","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment, Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"PVSj64zFvnRB1sTPHQixhek4bJOrc8qAwFjsNZaW692klOY16oThqk","news_summary":"3 Meme Stocks to Buy and Hold for Potential 300% Returns in 3 Years","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"rHaGt2GKC4FMzRLddmz2BTLgGbAKZ2Hi1r9wzedJSpTtoiWlexIRwy","date":"Jul 8, 2024","link":"https://finance.yahoo.com/news/3-meme-stocks-surge-200-195320230.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Meme Stocks, Investment","company":"Bitfarms, Archer Aviation, Entera Bio","layoffs":"Not mentioned","summary":"The article discusses the potential of three meme stocks - Bitfarms, Archer Aviation, and Entera Bio - to deliver high returns. Bitfarms, a Bitcoin miner, is expected to surge due to its revenue and EBITDA growth potential. Archer Aviation, an electric vehicle take-off and landing (eVTOL) company, is backed by Stellantis and United Airlines and is expected to commercialize eVTOL in the U.S. next year. Entera Bio, a clinical-stage biotech company, is working towards the commercialization of orally delivered peptides and other therapeutic proteins, with its most advanced product candidate, EB613, for the treatment of post-menopausal osteoporosis.","partners":"Stellantis, United Airlines","customers":"Not mentioned","investors":"Stellantis, United Airlines","confidence":8,"key_topics":"Meme Stocks, Investment, Crypto Mining, eVTOL, Biotech","date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"Growth-Positive","investment_amount":"Stellantis invested an additional $55 million in Archer Aviation","structured_issues":"Investment","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"FI3dLLKj870ZhpBLapm7KORKiWEVoj2JBSoGK4eAK9OVErvgB3vFHp","news_summary":"3 Meme Stocks That Can Surge by 200% Before 2025","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"76sytRc7SmdAWmBbZ3mf6lomgOTq9tLGrGhH8GKgn4CXsBN1da5xUL","date":"Jul 2, 2024","link":"https://finance.yahoo.com/news/3-clinical-stage-biotech-stocks-210556315.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Biotech, Clinical-stage, Investment","company":"Entera Bio, Adicet Bio, Actinium Pharmaceuticals","layoffs":"Not mentioned","summary":"The article discusses the potential of investing in clinical-stage biotech stocks, focusing on three companies: Entera Bio, Adicet Bio, and Actinium Pharmaceuticals. Entera Bio, valued at $63 million, has seen a 100% rally in the last 12 months and is developing EB613 for the treatment of post-menopausal osteoporosis. Adicet Bio has seen a 53% decline in the last 12 months but has received FDA approval for a fast-track designation for ADI-001. Actinium Pharmaceuticals has remained steady over the last 12 months and is developing Iomab-B, currently in Phase 3 clinical trials. The author suggests these stocks have the potential for significant returns over the next 24 to 36 months.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":8,"key_topics":"Clinical Trials, Biotech Stocks, Investment, Revenue Growth, Market Valuation","date_of_event":"Not mentioned","valuation_amount":"Entera Bio: $63 million","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":"Investment","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"iqPOKHBEznfRWGWFXm0QujG8AtUhd4m2OllFpuXkvzEDSQljnWKC7L","news_summary":"3 Clinical-Stage Biotech Stocks to Buy for Multibagger Returns","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"TK9M59CDvsGoEG5ZDqv1n8dknnCaxw3mXEK4iCgqvuVq9qY7VEamWO","date":"Jun 25, 2024","link":"https://finance.yahoo.com/news/3-meme-stocks-buy-dip-203707954.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Meme Stocks, Investment","company":"Novavax, GameStop, Riot Platforms, Aurora Cannabis, Entera Bio","layoffs":"Not mentioned","summary":"The article discusses the potential of certain meme stocks for investment. These include Riot Platforms, Aurora Cannabis, and Entera Bio. Riot Platforms is considered undervalued with strong fundamentals and a zero-debt balance sheet. Aurora Cannabis is expected to see action with the upcoming U.S. Presidential elections and potential for cannabis legalization. Entera Bio, a clinical-stage biotech company, is seen as a good opportunity to buy before the stock surges. The article suggests these stocks have potential for a rally and are good buys on the dip.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":8,"key_topics":["Meme Stocks","Investment","Stock Market","Fundamentals","Rally"],"date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"Growth-Positive","investment_amount":"Not mentioned","structured_issues":["Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"cxonLv0ssPQD0zA5I3znXtFysnZX1KK3MtJl2qvkEB0tZkw2Z7Etc1","news_summary":"3 Meme Stocks to Buy on the Dip: June 2024","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"tR9d5ATeA1kCNK08Ua9TojA5G0BYjPEHmcpRhk8nATNJPrws9Xla5n","date":"Jun 20, 2024","link":"https://finance.yahoo.com/news/rags-riches-3-penny-stocks-104700646.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Penny Stocks, Investment, Acquisition","company":"Joby Aviation, Entera Bio, Solid Power","layoffs":"Not mentioned","summary":"The article discusses three penny stocks with potential for significant growth: Joby Aviation, Entera Bio, and Solid Power. Joby Aviation, a flying car company, is expected to grow as the industry is estimated to reach $29 billion by 2030 and $1 trillion by 2040. The company recently acquired Xwing, a developer of autonomous technology for aviation. Entera Bio, a clinical-stage biotech company, has a promising product candidate, EB613, for high-risk post-menopausal osteoporosis treatment. Solid Power, a company focused on commercializing solid-state batteries, has the backing of major automotive players like BMW and Ford. The company is also deepening its partnership with SK On.","partners":"BMW, Ford, SK On","customers":"Not mentioned","investors":"BMW, Ford","confidence":8,"key_topics":["Penny Stocks","Investment","Acquisition","Growth","Market Potential"],"date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Investment","Acquisition"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment  #Acquisition","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"T9tvkd2P2CmR4tMj9wVqV6V3gApoD31mlmJhdYGAqNjzKq53hBVHQI","news_summary":"Rags to Riches: 3 Penny Stocks That Could Make Early Investors Rich","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"GkEG66sTnYwB4ka9P4E0ip6xAyzbFFsHsshdeueNTVtGLBcREwsDCf","date":"Jun 20, 2024","link":"https://finance.yahoo.com/news/7-penny-stocks-turn-3-163850409.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Investment, Expansion","company":"Bitfarms, Archer Aviation, Ring Energy, Standard Lithium, Entera Bio, Curaleaf Holdings, Blink Charging","layoffs":"NA","summary":"The article discusses seven penny stocks that are expected to deliver high returns over the next three years. These include Bitfarms, a Bitcoin miner with strong fundamentals and expansion plans; Archer Aviation, an eVTOL company with FAA certification and global expansion plans; Ring Energy, an oil & gas exploration company with a positive growth track record; Standard Lithium, a lithium company with a partnership with Equinor; Entera Bio, a biotech company with a promising pipeline; Curaleaf Holdings, a cannabis company with a presence in 17 states in the U.S. and expansion plans in Europe; and Blink Charging, an EV charging company with robust growth visibility.","partners":"Equinor","customers":"NA","investors":"Equinor","confidence":8,"key_topics":"Penny Stocks, Investment, Expansion, Revenue Growth, Market Valuation","date_of_event":"NA","valuation_amount":"Bitfarms: $124 million, Ring Energy: $308 million, Standard Lithium: $231 million, Curaleaf Holdings: $248 billion","impact_on_company":"growth-positive","investment_amount":"Equinor: $160 million","structured_issues":"Investment, Expand","acquisition_amount":"NA","structuredIssuesShow":"#Investment, Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"V9KRseYCte7MwS6XO6hKJo65z7DwWr7822UGDalXrrPQM9GwCJyxOu","news_summary":"7 Penny Stocks to Turn $3 Into $1 Million Within 36 Months","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"eaHySyRScw8v3F1HOf9rhpZcGozHBDZ6UhVShIDkTAVIBIwEJicwrJ","date":"Jun 17, 2024","link":"https://finance.yahoo.com/news/3-penny-stocks-turn-50-170000919.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Investment, Growth","company":"Cronos Group, Entera Bio, Blade Air Mobility","layoffs":"Not mentioned","summary":"The article discusses three high-risk penny stocks with potential for significant returns over the next three to four years. These include Cronos Group, a cannabis company with a strong balance sheet and cash buffer of $855 million, which is expanding into new markets. Entera Bio, a clinical-stage biotech company with a market valuation of $78 million, is working on orally delivered peptide and protein therapeutics for unmet medical needs. Blade Air Mobility, which provides air transportation alternatives to congested ground routes in the U.S., has an asset-light business model and robust growth outlook.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":7,"key_topics":"Penny Stocks, Investment, Growth, Cannabis, Biotech","date_of_event":"Not mentioned","valuation_amount":"Cronos Group: Not mentioned, Entera Bio: $78 million, Blade Air Mobility: Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":"Investment","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"FBfr5F0zI3dPuWIafieh19mM31ik3x53mTK5arfj1eKmfiMZ3xZPiw","news_summary":"3 Penny Stocks to Turn $50,000 Into $1 Million: June 2024","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"gMcyca0KwT7lxevX5YLx92riCDb5tBsf1EEZrwx5xORXNPBh5asMTf","date":"Jun 10, 2024","link":"https://finance.yahoo.com/news/under-10-picks-3-biotech-232244567.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Biotech Stocks, Investment","company":"Actinium Pharmaceuticals, Adicet Bio, Entera Bio","layoffs":"Not mentioned","summary":"The article discusses three biotech stocks under $10 that have impending catalysts. Actinium Pharmaceuticals, a clinical-stage biopharma company, has a cash buffer of $84 million expected to fund operations into the second half of 2026. Adicet Bio, a clinical-stage biotechnology company, received fast track designation from the U.S. Food and Drug Administration for ADI-001, a major catalyst for stock upside. Entera Bio, a clinical-stage biotech company, has cash runway through the first half of 2025 and multiple programs expected to enter clinical stage in 2025.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":8,"key_topics":["Biotech Stocks","Clinical Trials","Investment","Stock Market","Pharmaceuticals"],"date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"cnXyonpnk1KHctc8xERJ3m0lzUG9BPEJYyAG6uA8RaTt13Ud7kSRVs","news_summary":"Under-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ro2EGKTy8EUo6ys6c8jOBZlHLDWyaBQKsQJtaaz0AzvVffksJDm7Mv","date":"Jun 7, 2024","link":"https://finance.yahoo.com/news/meme-mania-meets-medicine-3-113000616.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Stock Market, Biotech","company":"Plug Power, Novavax, Atossa Therapeutics, Entera Bio, Actinium Pharmaceuticals","layoffs":"Not mentioned","summary":"The article discusses the impact of meme frenzy on biotech stocks, particularly those with ambitious growth plans. It highlights the example of Novavax, whose stock price increased by 328% in a month following news of a partnership with Sanofi. The article also identifies other biotech companies that could potentially see a similar surge, including Atossa Therapeutics, Entera Bio, and Actinium Pharmaceuticals. These companies are developing treatments for conditions such as breast cancer, osteoporosis, and cancer, and have seen significant stock price increases in the past year.","partners":"Sanofi","customers":"Not mentioned","investors":"Not mentioned","confidence":8,"key_topics":"Meme Stocks, Biotech, Clinical Trials, Stock Rally, Growth","date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":"Partners, Investment","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Partners, Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"vUDSAlH4a1GVL3wXtt2iuceVmVGhLOizMVT19nqQDncVdafUJ2uvt7","news_summary":"Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"tB2AzuV5uR35s6yrnERZQubKfifBwVDf9XyRWkJskAF8ZTqDeTF0a6","date":"Jun 3, 2024","link":"https://finance.yahoo.com/news/entera-bio-reports-phase-1-120000870.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Clinical Trials, Drug Development","company":"Entera Bio Ltd.","layoffs":"Not mentioned","summary":"Entera Bio Ltd. has announced Phase 1 clinical data for its hypoparathyroidism focused investigational program, EB612. The program aims to provide the first oral PTH daily tablet hormone replacement therapy for patients suffering from hypoparathyroidism. The data reported from this Phase 1 clinical study include pharmacokinetic (PK), pharmacodynamic (PD) and safety results from the application of a new generation of Entera’s N-Tab™ technology platform and EB612. The companys CEO, Miranda Toledano, stated that the findings reaffirm the ability of their N-Tab™ platform to develop simple oral tablet treatments of important peptide therapeutics.","partners":"Not mentioned","customers":"Patients suffering from hypoparathyroidism","investors":"Not mentioned","confidence":9,"key_topics":["Phase 1 clinical data","EB612 program","hypoparathyroidism treatment","N-Tab™ technology platform","oral peptide therapeutics"],"date_of_event":"June 03, 2024","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":"Investment","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"GRY0IL9NiBbJ7mzljS9n13DumPFdtpFhfA6d5Mjsif0u4t3ZQ15gMf","news_summary":"Entera Bio Reports Phase 1 Clinical Data of First-in-Class, Oral PTH(1-34) Peptide Candidate (EB612) for Patients with Hypoparathyroidism at ENDO 2024","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"9PmgkIhBfVzgwb8ZGtN1ZAAmVFl8hrhEQb05w6UlTVgDxSdiDd5irD","date":"Jun 3, 2024","link":"https://finance.yahoo.com/news/entera-bio-entx-outpaced-other-134009135.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Performance, Medical Stocks","company":"Entera Bio Ltd.","layoffs":"Not mentioned","summary":"Entera Bio Ltd. has been performing well in the medical sector, outperforming many other companies with a year-to-date return of about 275%. The companys earnings outlook has improved, with the Zacks Consensus Estimate for its full-year earnings moving 66.7% higher in the past quarter. The company currently has a Zacks Rank of #2 (Buy). Another medical stock that has been performing well is PetIQ, with a year-to-date return of 5.1% and a Zacks Rank of #1 (Strong Buy).","partners":"Not mentioned","customers":"Not mentioned","investors":"Zacks Investment Research","confidence":9,"key_topics":"Stock Performance, Medical Sector, Earnings Outlook, Year-to-Date Returns, Zacks Rank","date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":"Investment","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"CpOWo8ipTrdCurEH89RNeQqAZtlS5TBItYTLbXYK6YnDFrprOClkrP","news_summary":"Has Entera Bio (ENTX) Outpaced Other Medical Stocks This Year?","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"Iyt6oy44ddx3oPpIqb0nwD9UiTDlebw0tVKyu5w83BKZyA0oGMYH51","date":"May 23, 2024","link":"https://finance.yahoo.com/news/next-novavax-3-biopharma-stocks-104500605.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Partnership, Stock Growth","company":"Novavax","layoffs":"Not mentioned","summary":"Novavaxs stock, which had been lagging in the race for the COVID-19 vaccine, has seen a significant boost following a deal with Sanofi, with the stock increasing by 280% last month. The article suggests that with the potential return of the meme stock frenzy, now is a good time to invest in biotech stocks. It also discusses three other biotech stocks to consider: Acasti Pharma, Entera Bio, and Karyopharm Therapeutics. All three companies are working on promising drug pipelines and have potential for significant growth.","partners":"Sanofi","customers":"Not mentioned","investors":"Sanofi","confidence":8,"key_topics":["Stock Growth","Partnership","Biotech Stocks","Clinical Trials","Investment"],"date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$7.5 million (Acasti Pharma)","structured_issues":["Partners","Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"p06jN6jckXFZaudOihYNaom6ZkLAnaBLaHPh2JLIZFvyd5ytOQvzGc","news_summary":"The Next Novavax? 3 Biopharma Stocks to Buy Before They Boom","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"9GR5iARuyBMxPbMYoECQf5FRXvh78VLvRSi1jg2wsEYBqcYK1bmhtP","date":"May 16, 2024","link":"https://finance.yahoo.com/news/medical-stocks-lagging-entera-bio-134008853.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Stock Performance","company":"Entera Bio Ltd.","layoffs":"Not mentioned","summary":"Entera Bio Ltd. has been identified as a strong performer in the medical sector, with a year-to-date return of 336.7%, significantly outperforming the average return of 5.6% for the sector. The companys full-year earnings estimate has also increased by 66.7% in the past quarter, indicating a positive outlook. Another strong performer is Assembly Biosciences, with a year-to-date return of 48.4%. Both companies are recommended for investors interested in medical stocks.","partners":"Not mentioned","customers":"Not mentioned","investors":"Zacks Investment Research","confidence":9,"key_topics":["Medical Stocks","Investment","Stock Performance","Earnings Outlook","Year-to-date Returns"],"date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"RZzb49Pp6VyukPkKBSXu6Hn53m4b6W3K5FLDD7Lb8KGVoieelnkfhc","news_summary":"Are Medical Stocks Lagging  Entera Bio (ENTX) This Year?","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"Tfgb1JvDtJVqggvObTpH7s2eue2EgZuufvZpEhgO1EQUBOTAvurw69","date":"May 16, 2024","link":"https://finance.yahoo.com/news/vanda-vnda-rises-positive-data-152400376.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Pharmaceuticals, Clinical Trials","company":"Vanda Pharmaceuticals Inc.","layoffs":"Not mentioned","summary":"Vanda Pharmaceuticals Inc. has reported positive data from a second phase III study for its drug, tradipitant, which is being developed to prevent vomiting induced by motion sickness. The study confirmed earlier results that showed the drugs efficacy. The company plans to submit a new drug application for tradipitant to the FDA for the treatment of motion sickness in Q4 2024. The successful development and potential approval of tradipitant would address a significant patient population in the US, as around 30% of the population suffers from motion sickness under ordinary travel conditions.","partners":"Not mentioned","customers":"Not mentioned","investors":"Zacks Investment Research","confidence":9,"key_topics":["Clinical Trial","Tradipitant","Motion Sickness","FDA Approval","Stock Performance"],"date_of_event":"May 15","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"5d33oVhe8EIsjfsZ8Z7WafdClUODbNAYr3RmjMHDoVV4C02WtoeYIh","news_summary":"Vanda (VNDA) Rises on Positive Data From Motion Sickness Study","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"XbmVj6SMv4NcANzdxe3eKy6o8QVIvTWFVTLv3cw51NnHW8jv7a3uVe","date":"May 15, 2024","link":"https://finance.yahoo.com/news/entera-bio-appoints-dr-rachel-120000684.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Management Changes","company":"Entera Bio Ltd.","layoffs":"N/A","summary":"Entera Bio Ltd. has announced the appointment of Rachel B Wagman, MD, FACE, FACP, as Key Clinical Advisor and Member of its Scientific Advisory Board. Dr. Wagman brings over 20 years of experience in metabolic bone disease and women’s health research and drug development. She has successfully advanced the development of five molecules, including the osteoporosis products teriparatide (Forteo®), denosumab (Prolia®) and romosozumab (Evenity®) through clinical development, registration, and lifecycle management. The company believes her appointment will significantly benefit the continued development of their oral peptide pipeline.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":10,"key_topics":["Appointment","Clinical Advisor","Scientific Advisory Board","Oral Peptide Pipeline","Drug Development"],"date_of_event":"May 15, 2024","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Management Changes"],"acquisition_amount":"N/A","structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"LOVyF4UBzMcrIxinHfxbEOMax3LlYu79QzBxk7hmTupZ1Csx1QBzxV","news_summary":"Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"j2lhBHGUHoKzXWDns917UbxMT8o18ggaq2ufUHhM1ixJpTk30zqAsn","date":"May 13, 2024","link":"https://finance.yahoo.com/news/entera-bio-present-phase-1-110000251.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Research, Healthcare","company":"Entera Bio Ltd.","layoffs":"Not mentioned","summary":"Entera Bio Ltd. announced that it will present data for its investigational program EB612 at the Endocrine Society ENDO 2024 Annual Meeting. The EB612 program is being developed to provide the first oral PTH(1-34) tablet peptide replacement therapy for patients suffering from hypoparathyroidism. The data from the Phase 1 study includes PK and early PD results from the application of a new generation of Entera’s N-Tab™ technology platform with an unmodified PTH(1-34) peptide.","partners":"Not mentioned","customers":"Patients suffering from hypoparathyroidism","investors":"Not mentioned","confidence":9,"key_topics":["EB612 program","Hypoparathyroidism","Oral PTH(1-34) tablet","Endocrine Society ENDO 2024","Phase 1 Study"],"date_of_event":"May 13, 2024","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Customers"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"E62JNO9rXM7lJ5zF3yHRuTZnZUHsPJK3yguUYOETSORsTYY25AMyvc","news_summary":"Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"t6KAdWahXMcNsaXSlV67JUDlvgNIBoUZQeWosKsYm1qd9vGI3sw1y0","date":"May 10, 2024","link":"https://finance.yahoo.com/news/entera-bio-reports-q1-2024-201000113.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Financial Results, Therapeutic Development","company":"Entera Bio Ltd.","layoffs":"Not mentioned","summary":"Entera Bio Ltd. has reported positive financial results and key business updates for Q1 2024. The company has expanded its N-Tab™ therapeutic pipeline with potential first in class oral GLP-2, GLP-1/glucagon and PTH(1-34) peptide treatments for patients with GYN/endocrine, metabolic and gastrointestinal disorders. The company also announced positive in vivo PK results from its program combining OPKO Health, Inc.’s long acting GLP-2 analogue with N-Tab™ technology. As of March 31, 2024, Entera had cash and cash equivalents of $9.2 million and expects its existing cash resources to meet its projected operating requirements into the third quarter of 2025.","partners":"OPKO Health, Inc.","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Financial Results","Therapeutic Development","Partnership with OPKO","FDA Approval","Clinical Trials"],"date_of_event":"May 10, 2024","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Investment","Expand"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"XPbaThAHKc9t0ju0qbyKrHsTxwPciD2aDKV8PFVvQ5Ke3qRzAIx5vu","news_summary":"Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"l55Gj9R9LbJzixfLYe4MDz4LZ3Tys3JWa5bSl03y8QBj1AsBcHTIYo","date":"Apr 30, 2024","link":"https://finance.yahoo.com/news/medical-stocks-lagging-arbutus-biopharma-134010837.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Medical Stocks, Performance","company":"Arbutus Biopharma","layoffs":"Not mentioned","summary":"Arbutus Biopharma is outperforming its peers in the medical sector, according to Zacks Investment Research. The companys stock has returned 11.2% so far this year, compared to an average gain of 1.5% for medical stocks. The Zacks Consensus Estimate for Arbutus Biopharmas full-year earnings has also moved 0.9% higher over the past three months, indicating improving analyst sentiment and a positive earnings outlook. The company currently has a Zacks Rank of #2 (Buy).","partners":"Not mentioned","customers":"Not mentioned","investors":"Zacks Investment Research","confidence":9,"key_topics":["Medical Stocks","Stock Performance","Earnings Outlook","Zacks Rank","Year-to-date Returns"],"date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":"Investment","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"ZZfb9TOzFlhKAAztKcWzZS67FF0Ykdl5K6q25uJlRjCMJgqVzbPWpu","news_summary":"Are Medical Stocks Lagging  Arbutus Biopharma (ABUS) This Year?","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"Ag39dQI4Zf6FwDbCCU5eaAjN16B9vjiWQPcSOiHHaJT0gDf0HvCqVI","date":"Apr 26, 2024","link":"https://finance.yahoo.com/news/entera-bio-ltd-entx-stock-220014959.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Stock Performance, Investment","company":"Entera Bio Ltd.","layoffs":"Not mentioned","summary":"Entera Bio Ltd. saw a 1% decrease in its latest trading session, closing at $1.98. Despite this, the companys shares have gained 19.76% over the past month, outperforming the Medical sector and the S&P 500. The investment community is closely watching the companys upcoming earnings release, with expectations of a 25% increase from the prior-year quarter. The company currently holds a Zacks Rank of #1 (Strong Buy), indicating positive analyst forecasts. The Zacks Rank system has a strong track record of predicting stock performance.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":8,"key_topics":["Stock Performance","Investment","Earnings Performance","Analyst Forecasts","Zacks Rank"],"date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"ZXdtva8LsJN7pb3akEIuJsTZWJjLuEAjnEkTUBWRks6LKDrT9DRpDP","news_summary":"Entera Bio Ltd. (ENTX) Stock Slides as Market Rises: Facts to Know Before You Trade","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"dBNI3iNrWRJOYxi3NRpUkN9GWsYgEGfMcmdWhBi4B8wxNkEyxzfm8t","date":"Apr 18, 2024","link":"https://finance.yahoo.com/news/why-market-dipped-entera-bio-221519913.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Stock Performance","company":"Entera Bio Ltd.","layoffs":"Not mentioned","summary":"Entera Bio Ltd. saw a 0.9% increase in its recent trading session, closing at $2.24. This performance was ahead of the S&P 500s daily loss of 0.22%. Over the past month, the companys shares have gained 46.05%, outpacing the Medical sectors loss of 6.22% and the S&P 500s loss of 1.66%. The investment community is closely monitoring the companys performance ahead of its forthcoming earnings report. Analysts predict an EPS of -$0.06, indicating a 25% growth compared to the same quarter last year. The company currently carries a Zacks Rank of #1 (Strong Buy).","partners":"Not mentioned","customers":"Not mentioned","investors":"Zacks Investment Research","confidence":9,"key_topics":["Stock Performance","Investment","Earnings Report","Analyst Estimates","Zacks Rank"],"date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":"Investment","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"sJR43hOeDkQZWixhHc7pe4PMbY0xw2qkOY3BTo2ZoiAcJZxtpvefll","news_summary":"Why the Market Dipped But Entera Bio Ltd. (ENTX) Gained Today","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"LNih2Jit4HX8McAW8ytAyNltJJEscYWoFQw2Awb0RRCLXtAPSeyAh5","date":"Apr 15, 2024","link":"https://finance.yahoo.com/news/afford-ignore-3-biotech-stocks-194332352.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Biotech, Investment","company":"Alpine Immune Sciences, Entera Bio, Rezolute","layoffs":"Not mentioned","summary":"Biotech companies Alpine Immune Sciences, Entera Bio, and Rezolute have seen significant growth in their stock prices, surging over 160% year-to-date. Alpine Immune Sciences promising autoimmune drug, Povetacicept, has led to a substantial $4.9 billion buyout offer from Vertex Pharmaceuticals. Entera Bio has advanced its clinical pipeline, notably its leading compounds EB613 for osteoporosis and EB612 for hypoparathyroidism. Rezolute has seen increased investment from major shareholder and director Handok Inc., with two large stock purchases totaling approximately $17 million. All three companies have promising clinical trials and research collaborations underway.","partners":"Vertex Pharmaceuticals, Handok Inc.","customers":"Not mentioned","investors":"Vertex Pharmaceuticals, Handok Inc.","confidence":"8","key_topics":"Biotech Stocks, Investment, Clinical Trials, Drug Development, Stock Market","date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"Growth-Positive","investment_amount":"Vertex Pharmaceuticals $4.9 billion buyout offer for Alpine Immune Sciences, Handok Inc.s $17 million investment in Rezolute","structured_issues":"Investment","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"yeLhgHaSbHwRyrsO0bM4PvWKhf9RDjhYGIBRpleOpAzsLJ53D1ece5","news_summary":"Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"QtWSz4lyrvwhWHO9hZa0nYCgo5r0dFaS1mEiOJSsdwpQBcW361vckB","date":"Apr 12, 2024","link":"https://finance.yahoo.com/news/entera-bio-entx-outperforming-other-134009631.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"stock performance","company":"Entera Bio Ltd.","layoffs":"Not mentioned","summary":"Entera Bio Ltd. has been outperforming its peers in the Medical sector, with a year-to-date return of 343.3%, compared to the sectors average gain of 2.4%. The companys full-year earnings estimate has also increased by 66.7% over the past 90 days, indicating a positive earnings outlook. The company currently holds a Zacks Rank of #1 (Strong Buy). Another Medical stock, FibroGen, has also performed well this year, with a return of 53.5%.","partners":"Not mentioned","customers":"Not mentioned","investors":"Zacks Investment Research","confidence":8,"key_topics":["Medical stocks","Year-to-date performance","Zacks Rank","Earnings outlook","Sector performance"],"date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"cvOKiUAwQn04xQyqav0VxYqG6UL1smphEzUAmCfQ247Uk2Ov6QOXDv","news_summary":"Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"TwnyD9PJVXnnkzdUjTu5K50DBwXRNjTtXUmO6JckX2sQJDi37UhTCl","date":"Apr 9, 2024","link":"https://finance.yahoo.com/news/heres-why-invest-entera-bio-130900512.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Healthcare, Biotech","company":"Entera Bio","layoffs":"Not mentioned","summary":"Entera Bio, a biotech company that develops oral peptide therapies, has seen its stock surge 117.7% in the past year. The companys leading pipeline candidate is EB613, an oral tablet for treating osteoporosis. A phase IIb study of the EB613 tablets met the primary and secondary endpoints and the company plans to begin a phase III study once the FDA qualifies the treatment-related change in bone mineral density as a surrogate endpoint for fractures. Entera Bio also plans to advance five potential first-in-class oral peptide programs into clinical development in 2025.","partners":"Not mentioned","customers":"Not mentioned","investors":"Zacks Investment Research","confidence":8,"key_topics":"Oral Peptide Therapies, Osteoporosis, FDA Approval, Clinical Development, Stock Performance","date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":"Investment, Expand","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment, Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"uJ3llx0iWikNA2szxQyc15yPFO0UjH4WVUpyOt7HNUH8jcx1gFku0j","news_summary":"Here's Why You Should Invest in Entera Bio (ENTX) Stock Now","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"2S9afvN1nkJrede3Ut5l2YeXicdEnA4covBwntepJ6eZJLjkO3wbqx","date":"Apr 8, 2024","link":"https://finance.yahoo.com/news/entera-bio-announces-publication-oral-123000922.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Clinical Trial, Osteoporosis Treatment","company":"Entera Bio Ltd.","layoffs":"N/A","summary":"Entera Bio Ltd. has announced the publication of data from the Phase 2 Trial of its lead clinical compound, EB613, for the treatment of post-menopausal women with low bone mineral density (BMD) or osteoporosis. The study found that the highest dose of the oral tablet produced an increase in markers of bone formation while simultaneously decreasing the markers of bone breakdown. Significant gains in bone mineral density of the spine and hip were observed at the end of the 6-month study and there were no significant safety concerns. The company is preparing to initiate a Phase 3 registrational study for EB613.","partners":"N/A","customers":"Post-menopausal women with low BMD or Osteoporosis","investors":"N/A","confidence":9,"key_topics":["Clinical Trial","Osteoporosis Treatment","Oral Tablet","Bone Building","Phase 2 Study"],"date_of_event":"April 08, 2024","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Customers"],"acquisition_amount":"N/A","structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"e44xqLS224QOKT6UJ4n2baY3hGoItgkPDUxWOp5nqYy8w6BSDuutMR","news_summary":"Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"LGPJNUXL1detiZAK7v4XiHZF1C0CDClKzQX3lB6xJ5qLZd4QlDMMVm","date":"Mar 26, 2024","link":"https://finance.yahoo.com/news/entera-bio-announces-key-regulatory-123000201.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Drug Development, Regulatory Approval","company":"Entera Bio Ltd.","layoffs":"Not mentioned","summary":"Entera Bio Ltd. announced that the U.S. Food and Drug Administration (FDA) has communicated to the SABRE project team that a ruling to qualify the treatment-related change in bone mineral density (BMD) as a surrogate endpoint for fractures in future trials of new anti-osteoporosis drugs would be provided within 10 months. This is significant for Enteras lead clinical candidate, EB613, a first-in-class PTH(1-34) daily tablet treatment for osteoporosis. The company believes EB613 stands as the first program to potentially avail itself of the landmark SABRE initiative.","partners":"The American Society for Bone and Mineral Research (ASBMR), U.S. Food and Drug Administration (FDA)","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Drug Approval","Osteoporosis Treatment","Clinical Trials","FDA Communication","Bone Mineral Density"],"date_of_event":"March 26, 2024","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Investment","Expand"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"zKCOkxlOyKwdzJP0TtQQwIfDYX4vuLhFr3kf7CIfCspUuCTpjEcn7x","news_summary":"Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"jeCrgs4J69j1o5qyqvJjsHh8gneYT9tcCSZsdWjoo4BkkLzKIdu3ie","date":"Mar 25, 2024","link":"https://finance.yahoo.com/news/opko-health-opk-entera-bio-135700423.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Partnership, Research","company":"OPK Health, Inc.","layoffs":"N/A","summary":"OPK Health, Inc. and Entera Bio Ltd. have announced positive pharmacokinetic outcomes from their joint study that combines Enteras N-Tab technology with a long-acting, proprietary GLP-2 agonist created by OPK. The goal of the program is to create the first and only GLP-2 peptide pill substitute for individuals with short bowel syndrome (SBS) and other conditions that cause inflammation of the mucosa and loss of nutrients. The companies are looking forward to updating these data later in 2024.","partners":["Entera Bio Ltd."],"customers":"N/A","investors":"N/A","confidence":8,"key_topics":["Joint Study","Short Bowel Syndrome","GLP-2 Agonist","Pharmacokinetic Outcomes","Competition"],"date_of_event":"N/A","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Partners"],"acquisition_amount":"N/A","structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"sFsb5SBcmiv9hz9G3Qdrj9GrDOesVX9ovH7UUokUI9QJwMrjScUMsh","news_summary":"OPKO Health (OPK) And Entera Bio Announce Data for GLP-2","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"YR8MRv8b0j4QPqbwNZoT4yLAMdSXoWBImHyJRuK4w204U4kXHY8sxt","date":"Mar 24, 2024","link":"https://finance.yahoo.com/news/12-best-biotech-penny-stocks-195421471.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Investment, Acquisition, Expand","company":"Eli Lilly and Company","layoffs":"Not mentioned","summary":"The article discusses the growth and investment in the biotech sector, with a focus on Eli Lilly and Company. The company has seen a significant increase in investments and has made several acquisitions and collaborations, including DICE Therapeutics, POINT Biopharma, Versanis Bio, Emergence Therapeutics, Mablink Biosciences, Immunitrack, and Sigilon Therapeutics. The company also plans to expand its manufacturing capacity. The CEO of Eli Lilly, Dave Ricks, highlighted the companys efforts towards increasing the resilience of drug manufacturing and growing top lines through key partnerships. The companys revenue grew by 28% in Q4, with new products growing by over $2 billion.","partners":["DICE Therapeutics","POINT Biopharma","Versanis Bio","Emergence Therapeutics","Mablink Biosciences","Immunitrack","Sigilon Therapeutics"],"customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Investment","Biotech","Acquisition","Growth","Partnerships"],"date_of_event":"2024","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Investment","Acquisition","Expand"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment  #Acquisition  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"goULlp10W77Qr4lmNL76L5KkO2c988WE0Sf2foNwUrNNyd5hVhXDL0","news_summary":"12 Best Biotech Penny Stocks to Invest In","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"D8bS1PJZuHHbVXu8VV1Sb3IJwtjt4YJYX7rkC4VbLlbiznNkfxJckv","date":"Mar 23, 2024","link":"https://finance.yahoo.com/news/think-entera-bio-nasdaq-entx-131113118.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Cash Burn, Investment","company":"Entera Bio","layoffs":"Not mentioned","summary":"Entera Bio, a software-as-a-service business, has been losing money for years while growing its recurring revenue. Despite this, the companys cash burn rate has reduced by 42% over the last year, indicating some degree of prudence. As of December 2023, Entera Bio had US$11m in cash and was debt-free, with a cash runway of around 18 months. The companys cash burn relative to its market cap is quite good, and it is suggested that it would not have much trouble raising more cash for growth. However, this would result in some dilution for shareholders.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":8,"key_topics":["Cash Burn","Investment","Growth","Shareholders","Market Capitalisation"],"date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"Growth-Positive","investment_amount":"Not mentioned","structured_issues":["Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"dhyXOF0237Bu2dkr1rwsnaUraOiJdevQrJ6AulgLzIgevKFIicqI9y","news_summary":"We Think Entera Bio (NASDAQ:ENTX) Can Afford To Drive Business Growth","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"oxvDStRd7YpA2nioMWP7QakzbLFUf7dfXy46e23XUbPibJuFDWsLY9","date":"Mar 20, 2024","link":"https://finance.yahoo.com/news/entera-bio-announces-robust-pharmacokinetic-120000082.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Pharmaceutical Research","company":"Entera Bio Ltd.","layoffs":"Not mentioned","summary":"Entera Bio Ltd. has announced positive pharmacokinetic results from its research in collaboration with OPKO Health, Inc. The research is focused on developing the first and only GLP-2 peptide tablet alternative for patients suffering from short bowel syndrome and other disorders involving mucosal inflammation and nutrient malabsorption. The study’s objectives were met with oral GLP-2 tablets exhibiting significant systemic exposure. Entera and OPKO completed a proof of concept single dose pharmacokinetic study in rodents as the first validation for oral administration of the GLP-2 treatment.","partners":"OPKO Health, Inc.","customers":"Patients suffering from short bowel syndrome and other disorders","investors":"OPKO Health, Inc.","confidence":9,"key_topics":["Pharmacokinetic Results","GLP-2 Tablets","Short Bowel Syndrome","Collaboration with OPKO","Oral Peptide Therapy"],"date_of_event":"March 20, 2024","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Partners","Expand"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Partners  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"b49gFCGzeFPPCeIKXtikt41kUVvx9CAceIJ7Ejj7tSGd49sUyc7f7c","news_summary":"Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"2VyBZNHRVM4M3pJZqpMo75BN7xzPE7V6BYUFohg0JT5U7eFlircvPx","date":"Mar 8, 2024","link":"https://finance.yahoo.com/news/entera-bio-announces-full-2023-210500941.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Financial Results, Clinical Trials, Partnerships","company":"Entera Bio Ltd.","layoffs":"Not mentioned","summary":"Entera Bio Ltd. reported its financial results for the fourth quarter and year ended December 31, 2023. The company highlighted its progress in the development of orally delivered peptides, with five potential first-in-class oral peptide programs expected to advance into the clinic by the end of 2025. The company also reported a net loss of $8.9 million for the year ended December 31, 2023, compared to a net loss of $13.1 million for the year ended December 31, 2022. Entera Bio Ltd. expects to have sufficient cash to fund operations through the first half of 2025.","partners":"OPKO Health","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Financial Results","Clinical Trials","Partnerships","Drug Development","Funding"],"date_of_event":"March 08, 2024","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Partners","Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"2UjwC1x8XyK3HTue2BN7sB2b0jCjqixdszzfKlpY29NpYgWCWb7HpT","news_summary":"Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"iK1CPqqJt4DWlm8PXVkF4DFEV4p4k88sg1TOg0HX5J8MscmJrEIMRo","date":"Mar 4, 2024","link":"https://finance.yahoo.com/news/entera-bio-regains-compliance-nasdaq-133000784.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Compliance, Clinical Trials","company":"Entera Bio Ltd.","layoffs":"N/A","summary":"Entera Bio Ltd., a leader in the development of orally delivered peptides, has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on The NASDAQ Capital Market. The companys shares were required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days, which was achieved on March 1, 2024. Entera Bio is currently developing several oral peptide or protein replacement therapies for significant unmet medical needs.","partners":"OPKO Health","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["NASDAQ Compliance","Clinical Development","Oral Peptide Therapies","Product Candidates","Regulatory Approval"],"date_of_event":"March 04, 2024","valuation_amount":"N/A","impact_on_company":"Growth-Positive","investment_amount":"N/A","structured_issues":["Public Trading"],"acquisition_amount":"N/A","structuredIssuesShow":"#Public Trading","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"vyy0YfP1Sy6j7QVZVY1ZCfWVD9SPIKyJ6HigHJlhFnAlruy20eNntt","news_summary":"Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"mlhpuum0tSeoZ07081xrzo3nLktNoNUmVPXF6XZaYeld3PnTJMesn0","date":"Jan 30, 2024","link":"https://finance.yahoo.com/news/entera-bio-present-oppenheimer-34th-133000909.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Healthcare, Life Sciences","company":"Entera Bio Ltd.","layoffs":"Not mentioned","summary":"Entera Bio Ltd., a leader in the development of orally delivered peptides and therapeutic proteins, will participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference in February 2024. The companys CEO, Miranda Toledano, will present a business overview and update. Entera is a clinical stage company with a focus on developing oral peptide or protein replacement therapies. The companys pipeline includes five first-in-class oral peptide programs, expected to enter into the clinic (Phase 1 to Phase 3) by 2025.","partners":"OPKO Health","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Orally Delivered Peptides","Therapeutic Proteins","Healthcare Life Sciences Conference","Clinical Stage Company","Product Candidates"],"date_of_event":"Jan. 30, 2024","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":"Investment, Management Changes","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment, Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"hjteQFmiO9q7jd69LqKZ0Elz2V6hbSfkMrvvP4xw3f8TLG9Id3a0zo","news_summary":"Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"oXv2y5hxcrs2zEr4I0N0VfnaULDt3PfXuTsvByF3dMjUfdG0NiYujp","date":"Jan 3, 2024","link":"https://finance.yahoo.com/news/entera-bio-receives-extension-nasdaq-130000385.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Compliance, Stock Market","company":"Entera Bio Ltd.","layoffs":"N/A","summary":"Entera Bio Ltd., a leader in the development of orally delivered peptides and therapeutic proteins, has received an extension of 180 calendar days from the Nasdaq Stock Market to regain compliance with the Nasdaq’s minimum $1.00 bid price requirement for continued listing on the Nasdaq Capital Market. The company has until June 24, 2024, to regain compliance, and if it fails to do so, its shares will be subject to delisting. The notification from Nasdaq has no effect on the company’s business operations or on the listing or trading of the company’s shares.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["Nasdaq Compliance","Stock Price","Business Operations","Clinical Development","Therapeutic Proteins"],"date_of_event":"January 3, 2024","valuation_amount":"N/A","impact_on_company":"Neutral","investment_amount":"N/A","structured_issues":["Public Trading"],"acquisition_amount":"N/A","structuredIssuesShow":"#Public Trading","entityGrowthIconPath":"none;"},"sentiment":"Neutral","analysisId":"ca2eH8IkBB2D8Ki7x1I54P5nCg2yFOMJTCPSgU8Q9D288NxuzZp9cW","news_summary":"Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"MlbsPqD0h2GlaTnOcN3AR1TDknXkiyL8wi3azSf7VUbH8nWSojWTTQ","date":"Dec 26, 2023","link":"https://finance.yahoo.com/news/entera-bio-announces-closing-private-130000703.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Investment, Private Placement","company":"Entera Bio Ltd.","layoffs":"Not mentioned","summary":"Entera Bio Ltd., a leader in the development of orally delivered peptides and therapeutic proteins, announced that it has closed a private placement with certain existing and new investors on December 22, 2023. The company issued and sold 7,916,879 units at a price of $0.835 per unit, generating gross proceeds of approximately $6.6 million. This extends the companys cash runway into 2025. The company intends to use the net proceeds from the private placement for general working capital purposes. Network 1 Financial Securities Inc., consulted by Intuitive Venture Partners, acted as lead placement agent for the private placement.","partners":"Network 1 Financial Securities Inc., Intuitive Venture Partners","customers":"Not mentioned","investors":["Certain existing and new investors"],"confidence":"10","key_topics":["Private Placement","Investment","Orally Delivered Peptides","Therapeutic Proteins","Clinical Stage Company"],"date_of_event":"December 22, 2023","valuation_amount":"Not mentioned","impact_on_company":"Growth-Positive","investment_amount":"$6.6 million","structured_issues":["Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"FeeBcH50ibM1amRVyNTeZMd12RvSqHWtRRm748zJjApxc04BfUa9GX","news_summary":"Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"hAF5pLBwa853F4BxCLvxZwDP407214Y2fx8kEamTs1pv2uCWo09tSi","date":"Dec 25, 2023","link":"https://www.globenewswire.com/en/news-release/2023/12/26/2801081/0/en/Entera-Bio-Announces-Closing-of-Private-Placement-Extends-Cash-Runway-into-2025.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"Investment, Private Placement","company":"Entera Bio Ltd.","layoffs":"Not mentioned","summary":"Entera Bio Ltd., a leader in the development of orally delivered peptides and therapeutic proteins, has closed a private placement with certain existing and new investors. The company issued and sold 7,916,879 units at a price of $0.835 per unit, raising approximately $6.6 million. This extends the companys cash runway into 2025. If all warrants were exercised for cash, Entera would be entitled to receive additional proceeds of approximately $7.9 million. The company intends to use the net proceeds from the private placement for general working capital purposes.","partners":"Network 1 Financial Securities Inc., Intuitive Venture Partners","customers":"Not mentioned","investors":["Certain existing and new investors"],"confidence":9,"key_topics":["Private Placement","Investment","Orally Delivered Peptides","Therapeutic Proteins","Clinical Trials"],"date_of_event":"December 22, 2023","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$6.6 million","structured_issues":["Investment"],"acquisition_amount":"Not applicable","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Rat0jeTVKAWKRQswFFdSglIdScUl9lemkpohF6OhehQCWsIS2KB6jU","news_summary":"Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ZodhkHSx2q1nZgBXS12JUcrSOQetf6lhGTiQHA5qIb36EWqDb5q0gL","date":"Nov 29, 2023","link":"https://www.ice.co.il/digital-140/news/article/990506?_atscid=7_134353_204082920_2505032_0_Txtetaxjxdshwhus8sp","source":"www.ice.co.il","visible":1,"analysis":{"tags":"Innovation, Healthcare","company":"אנטרה ביו","layoffs":"N/A","summary":"Entera Bio, a leader in the development of orally delivered peptides and therapeutic proteins, has reported interim data from an ongoing Phase 1 study designed to evaluate and compare the early pharmacokinetic and pharmacodynamic profile of the current generation and several next-generation compositions of its oral peptide platform. The study initially compared the PK profile of Enteras Phase 3 candidate, once-daily oral mini-tablets of PTH(1-34) (EB613, also known as EBP05 formulation), with subcutaneous PTH(1-34) 20 μg (Forteo®).","partners":"N/A","customers":"Patients with osteoporosis","investors":"N/A","confidence":8,"key_topics":"Osteoporosis treatment, Clinical research, Peptide technology","date_of_event":"N/A","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":"Customers, Expand","acquisition_amount":"N/A","structuredIssuesShow":"#Customers, Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"9GZJKiHoRa287MSlXVQ3GKkns85S9VlkbJTJ8ysTfGWj4SULeqZduz","news_summary":"חברת אנטרה משיקה טיפול חדשני באוסטאופורוזיס","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"nEBcsQRIRVoQOuE5Zs1gl4lMUCS1qK22QOd9y2WA6o3WnDja3FCeFw","date":"Nov 29, 2023","link":"https://finance.yahoo.com/news/interim-results-ongoing-clinical-study-133000625.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Clinical Trials, Drug Development","company":"Entera Bio Ltd.","layoffs":"Not mentioned","summary":"Entera Bio Ltd. reported interim data from an ongoing Phase 1 study assessing the pharmacokinetic and early pharmacodynamic profile of its oral peptide platform. The study compared the profile of Enteras Phase 3 candidate, oral once-daily PTH(1-34) mini-tablets (EB613), with subcutaneous PTH(1-34) 20 g (Forteo). EB613 demonstrated a rapid and dose-proportional increase in plasma drug concentrations of PTH(1-34) at all doses tested. The companys next generation platform also showed robust bioavailability with novel oral peptide compositions. Entera is preparing to initiate a Phase 3 registrational study for EB613.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Phase 1 Study","Oral Peptide Platform","Osteoporosis Treatment","Next Generation Platform","Upcoming Conference"],"date_of_event":"Nov. 29, 2023","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Investment","Expand"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"OIG4duAdyIkYQKJIulNbqil2hbHYDzDONawbknNJ36yOiJapx325PE","news_summary":"Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera’s Next Generation Oral Peptide Platform","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"93dpLXWmz3xHlXuXUu8rLiucO2oVYsYoSkINE55u6j9v5ExsxvfGFv","date":"Nov 14, 2023","link":"https://finance.yahoo.com/news/entera-bio-reports-q3-2023-123000461.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Financial Results, Partnership, Research and Development","company":"Entera Bio Ltd.","layoffs":"Not mentioned","summary":"Entera Bio Ltd. has reported its Q3 2023 financial results and corporate updates. The company is focusing on the development of orally delivered peptides and small therapeutic proteins. It aims to move five high-value, first-in-class programs into the clinic by the end of 2025. The company has announced a collaboration with OPKO Health, Inc. to expand its oral delivery technology. Entera Bio has sufficient cash on hand to enable key read-outs from its significant pipeline expansion efforts over the coming year. As of September 30, 2023, Entera had cash and cash equivalents of $7.6 million.","partners":"OPKO Health, Inc.","customers":"Not mentioned","investors":"OPKO Health, Inc.","confidence":9,"key_topics":["Financial Results","Partnership with OPKO","Research and Development","Oral Peptide Programs","Corporate Updates"],"date_of_event":"Nov. 14, 2023","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Partners","Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"d4EIU093PCln6CUGZKqzZZM62zWhATce7p4lo4I4F34toE8o6BsI4H","news_summary":"Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"FG9OHeC4CSrT2os8TFOxLnkDYQ71Pa9AXjtvyUgSq0anWJbvSv4UVv","date":"Nov 9, 2023","link":"https://finance.yahoo.com/news/entera-bio-reports-key-milestone-193000108.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Drug Development, FDA Approval","company":"Entera Bio Ltd.","layoffs":"N/A","summary":"Entera Bio Ltd. has submitted a full qualification plan to the U.S. Food and Drug Administration (FDA) for the use of bone mineral density (BMD) as a surrogate endpoint for fractures in future trials of new anti-osteoporosis drugs. The submission is part of the SABRE project, which is the first surrogate endpoint undergoing qualification by the FDA under the 21st Century Cures Act. The companys EB613, an oral osteoanabolic tablet treatment for osteoporosis, could be the first program to use the BMD endpoint. Entera is preparing to initiate a Phase 3 registrational study for EB613.","partners":"American Society for Bone and Mineral Research, Foundation for the National Institutes of Health","customers":"N/A","investors":"N/A","confidence":9,"key_topics":"Osteoporosis Drug, FDA Approval, Clinical Trials, Bone Mineral Density, EB613","date_of_event":"Nov. 09, 2023","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":"Investment, Expand","acquisition_amount":"N/A","structuredIssuesShow":"#Investment, Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"nP9evuywtiIi5LT3B1WXr5wCiUHGpu0Nf0paOMvklfkyeW1VxyPsvK","news_summary":"Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for Osteoporosis","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"L5Aeh4N7VgxMENhHIrwUBkjn7EZ2Gf6xlmBwA2PtZe9yvvxNiTdpZI","date":"Oct 16, 2023","link":"https://finance.yahoo.com/news/entera-bio-reports-rapid-pharmacodynamic-120000787.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"3tmBpMwOhRxEWU1BRybCEpGtm4W8ObH6NIySuzb1gaTGr2twv6xpi5","news_summary":"Entera Bio Reports Rapid Pharmacodynamic (PD) Response and Consistent Pharmacokinetic (PK) Data for its First-in-Class Oral PTH(1-34) Mini Tablets at the ASBMR 2023 Annual Meeting","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"rsIjAu9rLhXOsH3LPRNn2TjiJcJMbi6yjawn0VUTzYET3NhgUNnB4I","date":"Sep 13, 2023","link":"https://finance.yahoo.com/news/opko-health-opk-ties-oral-171800834.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Partnership, Research Collaboration","company":"OPKO Health, Inc.","layoffs":"N/A","summary":"OPKO Health, Inc.’s subsidiary, OPKO Biologics, Inc., has entered into a Research Collaboration Agreement with Entera Bio Ltd. The agreement involves OPKO Health supplying its proprietary long-acting Glucagon-Like Peptide-2 (GLP-2) peptide and certain Oxyntomodulin (OXM) analogs for the development of oral tablet formulations using Entera’s proprietary oral delivery technology. Both companies will be responsible for specific phases of development of the two oral peptides. The partnership is expected to significantly strengthen OPKO Health’s global business.","partners":"Entera Bio Ltd.","customers":"N/A","investors":"N/A","confidence":8,"key_topics":["Research Collaboration Agreement","Oral Peptide Development","Peptide Therapeutics Market","Global Expansion","Pharmaceuticals Segment"],"date_of_event":"N/A","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Partners"],"acquisition_amount":"N/A","structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"BzzNDPnAX4TUEqFjdO3Og3P1SdkmJxrYrS9NevOnCDmKWYm2zRcOxq","news_summary":"OPKO Health (OPK) Ties Up for Oral Peptide Tablet Formulations","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"G2DKHjiv01rAWaVM3ZtNpmMABbOyYTNfk355hHEZlUNv1gV13CAZ9y","date":"Sep 12, 2023","link":"https://finance.yahoo.com/news/entera-bio-announces-collaboration-opko-123000997.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Partnership, Research Collaboration","company":"Entera Bio Ltd.","layoffs":"Not mentioned","summary":"Entera Bio Ltd. and OPKO Biologics, Inc., a subsidiary of OPKO Health, Inc., have entered into a Research Collaboration Agreement. Under the terms of the Agreement, OPKO will supply its proprietary long-acting GLP-2 peptide and certain Oxyntomodulin (OXM) analogs for the development of oral tablet formulations using Entera’s proprietary oral delivery technology. The collaboration will enable Entera to expand its oral delivery technology across additional high value peptides. OPKO has developed several proprietary, modified OXM analogs as potential candidates for treating obesity.","partners":"OPKO Biologics, Inc.","customers":"Not mentioned","investors":"OPKO Biologics, Inc.","confidence":9,"key_topics":["Research Collaboration Agreement","Oral Delivery Technology","Peptide Treatment","GLP-2 Peptide","Oxyntomodulin Analogs"],"date_of_event":"Sept. 12, 2023","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Partners"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"lqE10dkvxdVRzurYezS2yXHBSfEr4wn65E4EU3o4I5DtJpi10DiSTk","news_summary":"Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"QKxSfzFB3stoh7vN94IvQ2j03zVCvjoXGwj7zwXvkrbUiXViqJ8o2p","date":"Sep 5, 2023","link":"https://finance.yahoo.com/news/entera-bio-participate-upcoming-investor-120000530.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Investment, Management Changes","company":"Entera Bio Ltd.","layoffs":"Not mentioned","summary":"Entera Bio Ltd., a leader in the development of orally delivered peptides and therapeutic proteins, announced its participation in upcoming investor conferences. The companys CEO, Miranda Toledano, will be presenting at the H.C. Wainwright 25th Annual Global Investment Conference and the BIO Investor Forum. Entera is currently developing its most advanced product candidate, EB613, for the treatment of post-menopausal women with low BMD and high-risk osteoporosis. The company is also working on EB612 for the treatment of hypoparathyroidism and expects to report results from a phase 1B PK study in the second half of 2023.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Investor Conferences","Product Development","Clinical Trials","Financial Position","Regulatory Approval"],"date_of_event":"Sept. 05, 2023","valuation_amount":"Not mentioned","impact_on_company":"Growth-Positive","investment_amount":"Not mentioned","structured_issues":["Investment","Management Changes"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment  #Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"ch7QwBmYRLlJN71un64vYf6sbWajbQSNvAmqEpBzq2zNRDqmcdI629","news_summary":"Entera Bio to Participate in Upcoming Investor Conferences","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"twpUpi6652eanaUKwPI0oEeIQev58x3LMLHS41xFu2q5H6okyRIvQp","date":"Aug 24, 2023","link":"https://finance.yahoo.com/news/entera-bio-nasdaq-entx-good-102500105.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"cash burn","company":"Entera Bio","layoffs":null,"summary":"The article discusses Entera Bios cash burn rate and its impact on the company. It analyzes the companys cash reserves and cash runway, indicating that the end of the cash runway is in sight unless cash burn reduces drastically. The article also mentions that Entera Bio has reduced its cash burn by 34% over the last year. However, it raises concerns about the companys ability to raise more cash for growth, as its cash burn equates to about 39% of its market value. Overall, the article suggests that while there are some promising signs, the companys cash burn is risky and makes investors slightly nervous.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["cash burn","revenue growth","raising cash","market capitalization","warning signs"],"date_of_event":"June 2023","valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"UdtMB2Pfiqx06JnLegQkIAcuJWCOOfLpm7XiWgwangXzrhOYNU4tME","news_summary":"Is Entera Bio (NASDAQ:ENTX) In A Good Position To Invest In Growth?","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"a8Qr8yMexepUoh3wl5ye4CjAv7Z5uIWe7H7OurcSPFBviZUeM0lgTD","date":"Aug 16, 2023","link":"https://finance.yahoo.com/news/entera-bio-present-two-abstracts-123000229.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"development of orally delivered peptides and therapeutic proteins","company":"Entera Bio Ltd.","layoffs":null,"summary":"Entera Bio has been selected to present data for its investigational agent EB613 at the ASBMR 2023 Annual Meeting. EB613 is being developed as the first once-daily oral anabolic therapy for post-menopausal women with high-risk osteoporosis. The company aims to address the treatment gap in current osteoporosis care. The presentation will focus on the pharmacokinetic profile and the rapid pharmacodynamic effect of EB613. Entera Bio is a leader in the development of orally delivered peptides and therapeutic proteins. Its most advanced product candidates, EB613 and EB612, are in clinical development for the treatment of osteoporosis and hypoparathyroidism, respectively.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["EB613","osteoporosis","ASBMR 2023 Annual Meeting","oral anabolic therapy","post-menopausal women"],"date_of_event":"October 13-16, 2023","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"U9RvjEQUkEie6kfUVyHnV3vKW2i8TkF4Vu8u1mGTChLE7MopCis7jI","news_summary":"Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"v4wEsX8kZqo4UAD71qg8ppGWbWQMxMfmr8fCD7dhFsTFdkJThY4ZvD","date":"Aug 11, 2023","link":"https://finance.yahoo.com/news/entera-bio-announces-q2-2023-200500614.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Financial Results, Research and Development, Expansion","company":"Entera Bio Ltd.","layoffs":"Not mentioned","summary":"Entera Bio Ltd. has reported its financial results for Q2 2023 and provided updates on its corporate activities. The company has been focusing on three main areas: advancing its EB613 program, developing a new generation for EB612, and expanding its technological capabilities. The companys 2022 R&D plan resulted in pre-clinical validation of new generations of its oral peptide delivery platform. Entera Bio expects to announce data from its Phase 1B study of its new generation platform in H2 2023. The company also reported a net loss of $4.5 million for the six months ended June 30, 2023.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["EB613 Program","EB612 Development","Technological Capabilities","Financial Results","Expansion of IP Estate"],"date_of_event":"Aug. 11, 2023","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Investment","Expand"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"isGgqFG41AFWyCcXXSWzLCtGkDgpwWm7onksH2NKrg5neRGIhMHoOh","news_summary":"Entera Bio Announces Q2 2023 Financial Results and Corporate Updates","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"2hBxgWFDYUfI8MQYWpce2i5PFS2a02ImcpxppGko6ntVi9xRZrobnw","date":"Jun 7, 2023","link":"https://finance.yahoo.com/news/entera-bio-adds-sanofi-commercial-113000704.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"appointment","company":"Entera Bio Ltd.","layoffs":null,"summary":"Entera Bio has appointed Haya Taitel, Head of Sanofis Global Transplant Franchise, as an independent director to the Companys Board of Directors. Taitels experience in building commercial organizations and her expertise in late-stage product development and payor and channel strategies will be valuable as Entera prepares its global strategy for EB613s phase 3 program and future pipeline. Taitel recognizes the potential of EB613 and its unique positioning in treating post-menopausal women with osteoporosis. Entera aims to make a difference with its platform technology and core products, including EB613 and other pipeline candidates. Taitel has over 30 years of experience in the biopharma industry and currently serves as the Head of Sanofis Global Transplant Franchise.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["Appointment","Global Transplant Franchise","EB613","Platform Technology","Pipeline Candidates"],"date_of_event":"June 07, 2023","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Management Changes"],"acquisition_amount":null,"structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"n7ia5WgFyjnNX4aQ4xinCoKJqLCJYv1VepiFlwyQPsd8PqFARfLoxV","news_summary":"Entera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of Directors","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"YjBFUESAApeY6elRSFZI3ptBmjv5P9kJxEj30O7hSIYJISxxMNaGAk","date":"May 7, 2023","link":"https://finance.yahoo.com/news/entera-bio-first-quarter-2023-121021616.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"ShzZ6QtcV1PCHwKmCzz6jeFOgh9AahwggcpyMEcOERRpIMAJ9ihwT1","news_summary":"Entera Bio First Quarter 2023 Earnings: US$0.076 loss per share (vs US$0.13 loss in 1Q 2022)","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"FOWn2TwR7y06KQT9GnTNKhhmgqUw9TtT2iIZErWfoDHBORpkyA12kM","date":"May 5, 2023","link":"https://finance.yahoo.com/news/entera-bio-ltd-entx-reports-211509746.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"CCjtoAMp5ogMkfu5bzj4pZPfbWyu7JBsvpYomzMRy58dDJbyCvo3Mo","news_summary":"Entera Bio Ltd. (ENTX) Reports Q1 Loss, Misses Revenue Estimates","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"7I6mCRiN4vSx6u8M58cqO34ZmFIv7PMiV0eEg8RTGhv0BD9GnscKkF","date":"May 5, 2023","link":"https://finance.yahoo.com/news/entera-bio-announces-q1-2023-200500095.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"cawlrY2OYR5nPE6h3sOdaASFj8ibYFyUqGPsqXu80YT2pNgGOYF8Ux","news_summary":"Entera Bio Announces Q1 2023 Financial Results and Corporate Updates","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"aGKd96hqOoa27KNK1tbpeghBtzolCLfK6OsWyLl7XkvtLHZk3AVCIz","date":"May 4, 2023","link":"https://finance.yahoo.com/news/entera-bio-ltd-entx-report-140002193.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"zqGxxYPuXMMJZLzVa0InxXC2sbMmMbPc4snp7WT5LJ6v0XNDAw1gTq","news_summary":"Will Entera Bio Ltd. (ENTX) Report Negative Q1 Earnings? What You Should Know","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"hORuqHq5rIaqlRDw8o9fJ7U1VztBdEjLvJmX84JtbnxSAQqPjejrCW","date":"May 3, 2023","link":"https://finance.yahoo.com/news/entera-oral-delivery-glp-2-133400253.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"z5mkOF50WrVolhyNtYTfrmyK33QZ7Gofl1qx1A0zGQdwrurkttEx9x","news_summary":"Entera’s Oral Delivery of GLP-2 Pre-Clinical Data to be Published in Peer Reviewed, International Journal of Peptide Research and Therapeutics","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"QgH5L5zGjTfrrfdntD5fiy8dcjOkvnsF9J3g0ehwONqQWGbj1Yb1n2","date":"Apr 26, 2023","link":"https://finance.yahoo.com/news/menopause-luminary-dr-steven-r-123000298.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"tIUdd1Eq5ZLyuEQRqNgUzp5IwBifr1oZN1RO1lV8JhNlhsTJwp0QMC","news_summary":"Menopause Luminary, Dr. Steven R. Goldstein, Joins Entera’s Clinical and Scientific Advisory Board","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"jRRHbgVplvNuZtgff14dBweHa1bFGOAYb4aq5QxAIXafbZUUGXNr38","date":"Apr 3, 2023","link":"https://finance.yahoo.com/news/entera-bio-provides-guidance-fda-110000698.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"gtoYn43LLcfJ8YwxNI2PDt77u0pTYVR49CIYbrwDBozy4HrJmSYMq1","news_summary":"Entera Bio Provides Guidance from FDA Type D Meeting Related to EB613 Pivotal Program","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"YtjntPeNiC57Rf4g4r6WBEOBJubgeFpeSITVh7YCKirr8HG6fk7n00","date":"Mar 31, 2023","link":"https://finance.yahoo.com/news/entera-bio-ltd-entx-reports-211509741.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"gYQNN5eeq8cTIrarrtBbdavVMlAy2IayHL7bg0usdIusYpagUfaDB1","news_summary":"Entera Bio Ltd. (ENTX) Reports Q4 Loss, Lags Revenue Estimates","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"OKFQqfczJCFBGAw9op5Km1KJHD84GkKVlb4VlefbmNTEeoTBhUElDt","date":"Mar 31, 2023","link":"https://finance.yahoo.com/news/entera-bio-provides-2022-corporate-200000157.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"uZMCVlGjnHncdQtQ4je5QXpJNBuUSrmNrhU9bFx5KmAb25skQMODrV","news_summary":"Entera Bio Provides 2022 Corporate Milestones and Financial Results for the Year Ended December 31, 2022","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"Ie0Vz0TQsFvnZTV7kfkkKFfUdb0vvFskZM6eceIwlY5YJf2cob2yh0","date":"Mar 23, 2023","link":"https://finance.yahoo.com/news/entera-bio-regains-compliance-nasdaq-132700987.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"vHfDpMvfAhZCDHeh2iSjoaqmwLTbxoU32aWwoCQzVv7QwhbtkHMOOG","news_summary":"Entera Bio Regains Compliance with Nasdaq Listing Requirements","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"oIZHwZy8NZx6QvKtkKv0g9GXHh42nsnBk5DlfM84oVMCpXSqDsJ8S9","date":"Mar 10, 2023","link":"https://finance.yahoo.com/news/entera-bio-nasdaq-entx-spend-130558899.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Financial Health","company":"Entera Bio","layoffs":null,"summary":"Entera Bio, a pharmaceutical company, is facing concerns over its rate of cash burn. As of September 2022, the company had cash reserves of $14m and a cash burn of $13m over the trailing twelve months, giving it a cash runway of approximately 13 months. The companys cash burn has increased by 61% over the last year, which could lead to a significant reduction in its cash runway if the trend continues. Entera Bios cash burn equates to about 37% of its market value, indicating that it may need to issue new shares or take on debt to raise more cash.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["Cash Burn","Cash Runway","Share Dilution","Financial Risk","Investment Need"],"date_of_event":"September 2022","valuation_amount":"$35m","impact_on_company":"growth-negative","investment_amount":null,"structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"2JRhlkKNrtVtpK8Od8tN2qZiUWtV4fdwOY0m7kFvoFVNpUdPgRapMs","news_summary":"Will Entera Bio (NASDAQ:ENTX) Spend Its Cash Wisely?","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"WpaPAS5oBEgzmicW7V87qJJ8GYD34LhrKdjAOUx07DxBy8kZqpkj8G","date":"Feb 20, 2023","link":"https://finance.yahoo.com/news/entera-bio-entx-report-q4-133401812.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"fspRGMU1UZIbWDhf65P1vb864e0PH3ut2XWbouNahpUxpf9YSFQeKG","news_summary":"Entera Bio (ENTX) to Report Q4 Earnings: What's in the Cards?","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"JHbQQbCZnyjnj6kJLjtKRYDn8a7MqxrsBzrRNrFUvHQLmaWljwwEpg","date":"Feb 15, 2023","link":"https://finance.yahoo.com/news/entera-bio-announces-fda-acceptance-150000326.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"9EK4XFlcONZaCu8rmkjrtqGVaikEVjROzu9H48JjWy8tgo0703jwZr","news_summary":"Entera Bio Announces FDA’s Acceptance of a Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets, as the First Oral Osteoanabolic Treatment of Post-Menopausal Osteoporosis","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"H6g3ynfRDfnAF1jGC9HQN1IaXumnB6YBOD56OCqqUZksDsjb2C8Yxr","date":"Feb 13, 2023","link":"https://finance.yahoo.com/news/entera-bio-participate-svb-securities-140000103.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"fltFrMV51EbH96wBM8eBzspjvHPNUh3Bklpf4zDOacLcocmeJGVm9v","news_summary":"Entera Bio to Participate in the SVB Securities Global Biopharma Conference","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"9aB9NgMNu0EBX99xoc8pfwumDrskzlrVQlhsXkc2lBf3Wc0C62oKfS","date":"Feb 10, 2023","link":"https://finance.yahoo.com/news/entera-bio-ltd-entx-outpaces-230011857.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"72IyaxJdUUZFKYi3x1N7HnZFPHxurvI1miadxtIONP0tHrul8JOcg6","news_summary":"Entera Bio Ltd. (ENTX) Outpaces Stock Market Gains: What You Should Know","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"u3tGRElKkDlzuw7mDWR5p4ftenWnvGqDL0tvgFKMcuCGZb97gYFevx","date":"Feb 2, 2023","link":"https://finance.yahoo.com/news/entera-bio-ltd-entx-flat-230011448.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"PnNN7ZaKaQeu9pGsN4FqhwQYHUasHSAzqwtf8x1NPt4jNqduA654JZ","news_summary":"Entera Bio Ltd. (ENTX) Flat As Market Gains: What You Should Know","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"sZNQyIDtSWGFpJENYkX08h5oC5bqti94wpU1VncmlQhDDb6fnKvwcN","date":"Jan 27, 2023","link":"https://finance.yahoo.com/news/entera-bio-ltd-entx-stock-230011489.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"A4tZsjhwWnpnFHaf9njXOIQhYCjMh5BlWkWpVEZcigH92kMOcTTR5s","news_summary":"Entera Bio Ltd. (ENTX) Stock Sinks As Market Gains: What You Should Know","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"TA1txXELOFjZFAU3dYISr4efeqS5KWjYMh3VHBPGNR6L2RElW3VcJa","date":"Jan 25, 2023","link":"https://finance.yahoo.com/news/entera-bio-ltd-entx-flat-231511468.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"D9faTRxjr13odEpoTRgEkpdYfvLwUl7dKDumyeHR1IIGQbvEeGQ8eG","news_summary":"Entera Bio Ltd. (ENTX) Flat As Market Sinks: What You Should Know","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"85qZ2j1F4JiJny2i8LB1z9VH04S95tZGAhrIhq03dJhrIWrkGGfcpb","date":"Jan 18, 2023","link":"https://finance.yahoo.com/news/entera-bio-ltd-entx-gains-231511983.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"fuboNu7AtIEeT5YjwVAMe2NPC3gAXFjgfGEAcwXmtTuwRrLatzDgPP","news_summary":"Entera Bio Ltd. (ENTX) Gains As Market Dips: What You Should Know","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"52ZigRN128BFRajKTw5Twolyrg0fApjJDhwwW64UH7M1C9u666N3xh","date":"Nov 10, 2022","link":"https://www.globenewswire.com/news-release/2022/11/10/2553828/0/en/Entera-Bio-Provides-Corporate-Updates-and-Financial-Results-for-the-Third-Quarter-of-2022.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"Financial Results, Drug Development","company":"Entera Bio Ltd.","layoffs":"N/A","summary":"Entera Bio Ltd. has announced its Q3 2022 financial results and provided updates on its corporate activities. The company has achieved FDA agreement for a pivotal study of EB613, the worlds first daily bone-forming oral PTH tablet. The FDA has agreed that total hip bone mineral density, not fracture, could serve as the primary endpoint for the registrational study of EB613. The companys revenues for Q3 2022 were $8,000, compared to $140,000 for Q3 2021. As of September 30, 2022, Entera had cash and cash equivalents of $14.3 million.","partners":"Amgen","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["FDA Agreement","EB613","Financial Results","Clinical Trials","Osteoporosis Treatment"],"date_of_event":"Nov. 10, 2022","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Investment"],"acquisition_amount":"N/A","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"zRNK06auTSjdWCX0Le6PLQL3N7c4tSlNpxRSTFk8YTOGSvcWOGoT1f","news_summary":"Entera Bio Provides Corporate Updates and Financial Results for the Third Quarter of 2022","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"fCYQG6ddiGwZWk6QvTluX79QFWq7jmzhScr3nc3nJ6Uib0yteKiRba","date":"Oct 6, 2022","link":"https://finance.yahoo.com/news/entera-bio-announces-fda-agreement-110000125.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Drug Development, FDA Approval","company":"Entera Bio Ltd.","layoffs":"Not mentioned","summary":"Entera Bio Ltd. has announced the successful conclusion of its Type C meeting with the U.S. Food and Drug Administration (FDA). The FDA has agreed that a single Phase 3 placebo-controlled study could support a New Drug Application (NDA) submission of EB613, an oral treatment for post-menopausal osteoporosis patients. The FDA also agreed that Total Hip Bone Mineral Density (BMD) could serve as the primary endpoint for the registrational study of EB613. The company plans to initiate patient enrollment during 2023.","partners":"U.S. Food and Drug Administration, Amgen Inc.","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":"Drug Approval, Clinical Trials, Osteoporosis Treatment, FDA Meeting, EB613","date_of_event":"Oct. 06, 2022","valuation_amount":"Not mentioned","impact_on_company":"Growth-Positive","investment_amount":"Not mentioned","structured_issues":"Investment, Expand","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment, Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"ExOpV04PKtpLeFkT52FSgyalcRjG6Cydhtm5Pvaf341GKcL2HESg8H","news_summary":"Entera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of Osteoporosis","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"JVMzoHpR8VNxBvkB6i1MeUVUV3iY9RjkS9uik30RTdFT7Cp6s139OG","date":"Sep 12, 2022","link":"https://www.globenewswire.com/news-release/2022/09/12/2513810/0/en/Entera-Bio-Presents-Dose-Proportional-Absorption-and-Correlation-to-BMD-Clinical-Response-Data-from-its-Phase-2-Study-of-EB613-in-Post-Menopausal-Osteoporosis-Patients-at-the-ASBMR.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"oral drug delivery, osteoporosis treatment, clinical study","company":"Entera Bio Ltd.","layoffs":null,"summary":"Entera Bio announced the details of a six-month Phase 2 study of their oral PTH formulation, EB613, in postmenopausal women with low bone mass. The study showed positive results, with a strong correlation between the dose of EB613 and teriparatide plasma concentrations, as well as a linear dose response for the change in lumbar spine bone mineral density (BMD) after 6 months of treatment. The company is encouraged by these findings and highlights the potential of EB613 as a convenient, daily tablet form of osteoanabolic treatment for osteoporosis. Entera Bio is a leader in the development of orally delivered macromolecules therapeutics and has a proprietary oral drug delivery technology. Their most advanced product candidates, EB613 and EB612, are in clinical development for the treatment of osteoporosis and hypoparathyroidism, respectively.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["Phase 2 Study","Oral PTH","Bone Mass","Lumbar Spine BMD","Osteoporosis Treatment"],"date_of_event":"September 12, 2022","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"2afYJCV8gvT3JKuQfVAoOsg0YDO19nPs1wmCf1kngm3CfPIf8jkjqW","news_summary":"Entera Bio Presents Dose Proportional Absorption and Correlation to BMD Clinical Response Data from its Phase 2 Study of EB613 in Post-Menopausal Osteoporosis Patients at the ASBMR 2022 Annual Meeting","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"xDZxNOrZApmuepYMoL7bkP220BBuG8vFv86xvMqIDIH5kYiXLaI2FJ","date":"Jul 26, 2022","link":"https://www.globenewswire.com/en/news-release/2022/07/26/2485783/0/en/Entera-Bio-Announces-Formation-of-Clinical-and-Scientific-Advisory-Board-and-Poster-Presentation-at-ASBMR-2022-Annual-Meeting.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"clinical development","company":"Entera Bio Ltd.","layoffs":null,"summary":"Entera Bio has announced the formation of its Clinical and Scientific Advisory Board (CSAB) and the presentation of new data from its Oral PTH Phase 2 Study at the 2022 Annual Meeting of the American Society for Bone and Mineral Research. The CSAB consists of experts in bone diseases, endocrinology, and metabolic disorders. The study focuses on postmenopausal women with low bone mass and osteoporosis. The results showed a statistically significant increase in bone mineral density (BMD) in subjects receiving the oral PTH treatment. Entera Bios proprietary oral drug delivery technology aims to address the challenges of poor absorption and variability in large molecule therapeutics. The companys most advanced product candidates, EB613 and EB612, are in clinical development for the treatment of osteoporosis and hypoparathyroidism, respectively.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["Clinical and Scientific Advisory Board","Oral PTH Phase 2 Study","American Society for Bone and Mineral Research","EB613","osteoporosis"],"date_of_event":"September 9-12, 2022","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"v8CjwVIBx2tN1j6VEHAA5RKtVBhHU8pNzSvQVKKBQnXnfwXpVEeuzL","news_summary":"Entera Bio Announces Formation of Clinical and Scientific Advisory Board and Poster Presentation at ASBMR 2022 Annual Meeting","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"aTXTMnd4bCiVqIbBBbz98Mv6awFfjWcBjotT8laTEI1BVsS2KttbUz","date":"Jun 17, 2022","link":"https://www.globenewswire.com/en/news-release/2022/06/17/2464934/0/en/Entera-Bio-Announces-Departure-of-Dr-Phillip-Schwartz-the-Company-s-President-of-Research-Development-to-Pursue-Outside-Opportunities.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":["management changes"],"company":"Entera Bio Ltd.","layoffs":null,"summary":"Dr. Phillip Schwartz, the President of Research & Development and Founder of Entera Bio Ltd., has announced his resignation from his current role effective July 21, 2022. Dr. Schwartz will remain as a consultant to the company. His resignation was not due to any disagreement with the company. Entera Bio has recently announced new leadership to carry out Dr. Schwartzs vision for the company. Dr. Schwartz expressed confidence in the new management team and their ability to move Entera forward. The company is focused on the development of orally delivered peptides and therapeutic proteins for areas with unmet medical needs. Their lead compound, EB613, is moving into Phase 3 clinical development for the treatment of osteoporosis. Entera Bio also has a collaboration with Amgen Inc.","partners":["Amgen Inc."],"customers":null,"investors":null,"confidence":8,"key_topics":["resignation","leadership","clinical development","strategic goals","shareholder value"],"date_of_event":"July 21, 2022","valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":["Management Changes"],"acquisition_amount":null,"structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"HaX7gxQOXJMK9TRrti54KEJlAN3FBJDNVGhRw8ITU6vu5CKtNofMHe","news_summary":"Entera Bio Announces Departure of Dr. Phillip Schwartz, the Company's President of Research & Development to Pursue Outside Opportunities","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"843ca87c-d51b-4369-bcbb-e911084e9492","date":"Jun 24, 2021","link":"https://www.globes.co.il/news/article.aspx?_atscid=7_134353_204082920_1900410_0_Txtetaxjxdshwhus8sp&did=1001375825","source":"www.globes.co.il","visible":1,"analysis":{"tags":"Pharmaceuticals, Clinical Trials","company":"אנטרה ביו","layoffs":"N/A","summary":"Antera Bio, a company developing oral medications as an alternative to injections for osteoporosis and other bone diseases, has reported positive results from a trial. Patients who received the drug gained bone mass in the spine, and the difference between the drug group and the placebo group was significant. Following the announcement, the companys stock rose by 44% and is now traded at a value of $154 million on NASDAQ. The company plans to enter a phase III trial, which may be the last before marketing. If the product gives good results, the company will likely be able to register its product for marketing, making it the first oral osteoporosis drug approved for marketing in the US.","partners":"Amgen","customers":"N/A","investors":"N/A","confidence":8,"key_topics":["Clinical Trial","Osteoporosis Treatment","Stock Increase","Partnership","Future Plans"],"date_of_event":"N/A","valuation_amount":"$154 million","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Customers","Partners"],"acquisition_amount":"N/A","structuredIssuesShow":"#Customers  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"1cAiwcA0zRXvL3yFTU2H6zw9EYFoS0VHdPenO1c83LsutG6O2jDdBJ","news_summary":"אנטרה ביו פרסמה תוצאות טובות לטיפול באוסטיאופורוזיס","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"c166b90b-e1bb-463c-be6f-728ee6107270","date":"Jun 17, 2021","link":"https://www.globenewswire.com/news-release/2021/06/17/2248925/0/en/Entera-Bio-Receives-Foundational-Patent-for-its-Oral-PTH-using-its-Platform-Oral-Protein-Delivery-Technology-in-European-Union.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":["patent","oral delivery technology","large molecule therapeutics"],"company":"Entera Bio Ltd.","layoffs":null,"summary":"Entera Bio has been granted a patent by the European Patent Office for its oral delivery technology for large molecule therapeutics. The patent covers Enteras oral PTH formulations for the treatment of osteoporosis and hypoparathyroidism. This patent adds to the companys existing patents in strategic countries including the USA, China, Japan, Australia, New Zealand, and Israel. Entera CEO Spiros Jamas stated that the patent provides robust protection of the companys intellectual property and strengthens its leadership position in the oral delivery of proteins. Entera is currently in Phase 2 clinical development for its product candidates EB613 for osteoporosis and EB612 for hypoparathyroidism. The companys oral drug delivery technology addresses the challenges of poor absorption and high variability of large molecules.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["patent","oral delivery technology","large molecule therapeutics","osteoporosis","hypoparathyroidism"],"date_of_event":"June 17, 2021","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"5MQhz00knOTk7fSHbJfiXNK8494rz2ehc4qw117tVsQwqEBtsFGvOj","news_summary":"Entera Bio Receives Foundational Patent for its Oral PTH using its Platform Oral Protein Delivery Technology in European Union","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"08ab11bd-0627-42ac-b7ee-3c9690cd6065","date":"Apr 13, 2021","link":"https://seekingalpha.com/article/4418883-first-look-entera-bio","source":"seekingalpha.com","visible":1,"analysis":{"tags":"biopharma","company":"Entera Bio","layoffs":null,"summary":"Entera Bio, an Israeli-based biopharma company, has reported positive trial results for its candidate EB613 to treat osteoporosis. The company plans to pursue approval for EB613 in the US and is seeking FDA guidance for a Phase 3 clinical trial. Entera Bio also has another drug candidate, EB612, which has been granted Orphan Drug designation but has faced delays in development. Analysts have shown optimism towards Entera Bio, with increased price targets. The company has a collaboration deal with Amgen and is looking for new partners to fund and assist with development. The companys cash position is expected to fund operations until Q2 2022.","partners":["Amgen"],"customers":null,"investors":null,"confidence":8,"key_topics":["Entera Bio","biopharma","trial results","osteoporosis","drug candidates"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"z8R9vSy05yEcsOy7M8b9QSKhtG2MONMFpTGeep2s5ilPvJ11T9QNjZ","news_summary":"Our First Look At Entera Bio (NASDAQ:ENTX)","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"f8f1156f-8b41-44aa-bce5-60afe9da0214","date":"Nov 9, 2020","link":"https://www.globenewswire.com/news-release/2020/11/09/2122812/0/en/Entera-Bio-Ltd-Announces-Completion-of-Enrollment-In-Phase-2-Clinical-Trial-of-Eb613-In-Osteoporosis.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":["clinical trial","osteoporosis","oral bone building product"],"company":"Entera Bio Ltd.","layoffs":null,"summary":"Entera Bio Ltd. has completed enrollment in the Phase 2 clinical trial of EB613, an orally delivered human parathyroid hormone (1-34) for the treatment of osteoporosis. The trial showed positive results, with a significant dose-dependent trend in lumbar spine bone mineral density (BMD) increase. The company expects to report interim 3-month biomarker data for all enrolled patients in Q1:21 and final BMD data in Q2:21. The results will inform the design of a potential global Phase 3 clinical trial. Entera Bio has sufficient funds to support its operations until Q2:21.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["Phase 2 clinical trial","EB613","osteoporosis","oral bone building product","BMD data"],"date_of_event":"2020-11-09","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"vkorHp1DRXRgx6HwwGyUvK4hOnMhOA8cq4nhTWKoeWmNE50Ehsj8P6","news_summary":"Entera Bio Ltd Announces Completion of Enrollment In Phase 2 Clinical Trial of Eb613 In Osteoporosis","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"580071b5-02d1-4254-9b14-946b3f0edf34","date":"Jul 22, 2020","link":"https://www.nasdaq.com/press-release/entera-bio-ltd.-announces-highly-encouraging-oral-pth-market-survey-results-2020-07","source":"www.nasdaq.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"eIhq2mL6QfWbmB6rPwjbTD46Ml6kgjQSl2yGFQPjuaHzFeKtKBc7Go","news_summary":"Entera Bio Ltd. Announces Highly Encouraging Oral PTH Market Survey Results","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"323f6a44-a435-443b-9dd0-4d0f54e577f3","date":"Jul 7, 2020","link":"https://www.globenewswire.com/news-release/2020/07/07/2058583/0/en/Entera-Bio-Ltd-Provides-Update-on-Phase-2-Clinical-Trial-of-EB613-in-Postmenopausal-Women-With-Osteoporosis.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":["Phase 2 protocol","biomarker data","dose response","patient enrollment","osteoporosis drug","oral drug delivery technology","Phase 3 clinical trial","macromolecule therapeutics"],"company":"Entera Bio Ltd.","layoffs":null,"summary":"Entera Bio Ltd. has received approval from Institutional Review Boards (IRBs) to amend its Phase 2 protocol for testing higher doses of EB613, an orally delivered PTH 1-34 for the treatment of osteoporosis. The interim Phase 2 biomarker and safety data showed positive effects of EB613 on bone remodeling, leading to the evaluation of higher doses in the trial. The two lower doses have been discontinued, and new patient enrollment now includes a 2.5 mg dose, 1.5 mg dose, and placebo. The company expects to complete enrollment in Q3:20 and plans to report biomarker and six-month BMD data in early Q1:21 and early Q2:21, respectively. If successful, Entera intends to meet with the FDA to discuss the results and design a potential Phase 3 clinical trial for regulatory approval.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["Phase 2 protocol","EB613","osteoporosis","oral drug delivery","clinical trial"],"date_of_event":"July 07, 2020","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers","Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Customers  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"tZKZ41NSUiHScRBimgBnz8UnB11chCgk4F60sINNOZdLvx9Avjnzm9","news_summary":"Entera Bio Ltd Provides Update on Phase 2 Clinical Trial of EB613 in Postmenopausal Women With Osteoporosis","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"33a94e15-0b71-4b68-9f0c-830b5ed4d0fc","date":"Jan 27, 2020","link":"https://rivertonroll.com/news/2020/01/27/short-interest-in-entera-bio-ltd-nasdaqentx-grows-by-800-0.html","source":"rivertonroll.com","visible":1,"analysis":{"tags":"Stock Market, Biopharmaceutical","company":"Entera Bio","layoffs":"Not mentioned","summary":"Entera Bio, a clinical-stage biopharmaceutical company, is expected to see a decrease in earnings in the coming year, from ($0.31) to ($0.76) per share. However, the companys stock has a forecasted upside of 755.7% from its current price of $0.88, according to analysts consensus price target of $7.50. Entera Bios lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis. The company has a research collaboration and license agreement with Amgen Inc.","partners":"Amgen Inc.","customers":"Not mentioned","investors":"Not specified","confidence":8,"key_topics":"Stock Performance, Clinical Trials, Product Candidates, Analyst Ratings, Earnings","date_of_event":"07/3/2023","valuation_amount":"$25.24 million","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":"Investment","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Kdq24UqLDMVGPzcT0Gu9xhbHNCrLmDWXF0nnJByYaOtxKwThyVl9xz","news_summary":"Entera Bio Stock Forecast, Price & News (NASDAQ:ENTX)","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"f6218a0b-a619-48ad-a487-2587b757c5e3","date":"Dec 12, 2018","link":"https://www.prnewswire.com/news-releases/frost--sullivan-publishes-immediate-report-on-dna-biomedical-solutions-ltd-300764304.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"research and development","company":"Entera Bio Ltd.","layoffs":null,"summary":"Entera Bio Ltd., a subsidiary of DNA, has announced a research and development agreement with pharmaceutical giant Amgen for pre-clinical drug candidates. The agreement allows Entera to use its proprietary drug delivery platform to develop oral versions of one preclinical large molecule program selected by Amgen. Entera could receive up to $270 million in aggregate payments and tiered royalties. The company will retain IP rights to its technology. This collaboration demonstrates the clinical and economic potential of Entera. The target price for Entera remains unchanged at $0.33 per share.","partners":["Amgen"],"customers":null,"investors":null,"confidence":8,"key_topics":["research collaboration","drug delivery platform","Amgen","clinical potential","economic potential"],"date_of_event":"2018-12-11","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"E93UWrBPHDUl7q8m7nJbOy63Te3kpSlGLYjNedDIIfmXpnDz6DFgTd","news_summary":"Frost & Sullivan Publishes Immediate Report on DNA Biomedical Solutions Ltd.","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"5dc44ccc-a05e-4ae1-b6cb-f96f77191ada","date":"Dec 11, 2018","link":"https://en.globes.co.il/en/article-entera-bio-signs-270m-amgen-licensing-deal-1001264362","source":"en.globes.co.il","visible":1,"analysis":{"tags":"research collaboration, license agreement, drug delivery platform, milestone payments, royalties","company":"Entera Bio Ltd.","layoffs":null,"summary":"Entera Bio has entered into a research collaboration and license agreement with Amgen in inflammatory disease and other serious illnesses. The agreement could be worth up to $270 million in milestone payments and royalties. Entera will use its proprietary drug delivery platform to develop oral formulations for one preclinical large molecule program that Amgen has selected. Amgen also has an option to select up to two additional programs to include in the collaboration. Entera will receive a modest initial technology access fee from Amgen and will be responsible for preclinical development at Amgen’s expense. Entera will retain all IP rights to its drug delivery technology, which will be licensed exclusively to Amgen for Amgen’s nominated drug targets.","partners":"Amgen","customers":null,"investors":null,"confidence":9,"key_topics":["research collaboration","license agreement","drug delivery platform","milestone payments","royalties"],"date_of_event":"December 11, 2018","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"MpMCNEDpGKhLPHkAerIUgNVrh8rvpCZlEiYTH5xRl8LtugSdILvB8f","news_summary":"Entera Bio signs $270m Amgen licensing deal","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"c6e0d709-8919-4e49-ac78-6e4f239ca989","date":"Jul 1, 2018","link":"http://en.globes.co.il/en/article-osteoporosis-co-entera-bio-lists-on-nasdaq-at-fourth-attempt-1001243961","source":"en.globes.co.il","visible":1,"analysis":{"tags":"investment","company":"Entera Bio","layoffs":null,"summary":"Israeli drug development company Entera Bio has raised $11 million on Nasdaq at a company valuation of $91 million. The company is developing treatments for osteoporosis and a rare thyroid condition. This was their fourth attempt to list on Nasdaq.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["Israeli drug development company","raised $11 million","Nasdaq","company valuation","treatments for osteoporosis and a rare thyroid condition"],"date_of_event":"July 1, 2018","valuation_amount":"$91 million","impact_on_company":"growth-positive","investment_amount":"$11 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"E1WonsyJWIHdlta2Z0t6xDlZX6j0JxRhDn18xTuD9Z5nVlM9SrHmgi","news_summary":"Entera Bio lists on Nasdaq at fourth attempt","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"5bf54ab3-c1d4-44a6-b9bc-8ae5f86d38ed","date":"May 21, 2018","link":"https://www.calcalistech.com/ctech/articles/0,7340,L-3738464,00.html","source":"www.calcalistech.com","visible":1,"analysis":{"tags":"IPO","company":"Entera Bio Ltd.","layoffs":null,"summary":"Jerusalem-based biomed company Entera Bio Ltd. has filed for an initial public offering (IPO) on Nasdaq for the fourth time since 2014. The IPO is expected to have a positive impact on the companys growth. Entera is a clinical stage company focused on developing technology for the oral delivery of large molecule-based drugs. It aims to provide treatments for osteoporosis, bone disorders, and the orphan disease hypoparathyroidism. Entera has previously raised $26.5 million, with its latest funding round of $13 million completed in October 2017. The IPO details and timeline have not been disclosed. Entera is a subsidiary of D.n.a Biomedical Solutions Ltd., which holds a 27% stake in the company.","partners":null,"customers":null,"investors":"Undisclosed investors","confidence":9,"key_topics":["IPO","Biomed","Drug delivery","Clinical stage","Orphan disease"],"date_of_event":"2018-05-21","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Public Trading"],"acquisition_amount":null,"structuredIssuesShow":"#Public Trading","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"6AFDrVfO7ACu4PZsCKdG8chZI0djIwubAvU9DVx4j5rzy234A3f8xo","news_summary":"Entera Bio Gives Nasdaq IPO Another Shot","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"e22554da-4657-4a4b-8095-c19d1bb89168","date":"Nov 12, 2017","link":"http://www.globes.co.il/en/article-entera-bio-files-for-50m-nasdaq-ipo-1001211392","source":"www.globes.co.il","visible":1,"analysis":{"tags":"biotech, IPO","company":"Entera Bio","layoffs":null,"summary":"Entera Bio, a subsidiary of DNA Biomedical Solutions, has filed for a Nasdaq IPO to raise up to $50 million. The company develops drugs for hypoparathyroidism, osteoporosis, and bone healing. It recently raised $12.5 million in a bridge private placement financing round. Phase II/III trials for the hypoparathyroidism treatment are set to begin in Q1 2018. The drug has received FDA orphan status for the treatment of rare diseases.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["Phase II/III trials","hypoparathyroidism treatment","Nasdaq IPO","bridge private placement financing","FDA orphan status"],"date_of_event":"November 12, 2017","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Public Trading","Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Public Trading  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"uyFz6OhBVX0UqGt5y9rWes9xkAsgQpF0NYHEiwwk9Roovcyx9U8fop","news_summary":"Entera Bio files for $50m Nasdaq IPO","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"e81e683d-b507-4ef9-812b-483964808612","date":"Sep 13, 2017","link":"http://www.globes.co.il/en/article-entera-bio-raising-10-at-94m-valuation-1001205006","source":"www.globes.co.il","visible":1,"analysis":{"tags":"drug development","company":"Entera Bio","layoffs":null,"summary":"Entera Bio plans to raise $10 million at a company value of $94 million to develop a drug for the treatment of osteoporosis and primary hypoparathyroidism. DNA Biomedical Solutions Ltd. will invest $5 million and own 30% of Entera. Other potential investors include the Pontifax fund and individuals associated with Kite Pharma. Enteras products are based on technology that allows for oral administration of drugs. A phase II/III trial for a drug to treat primary hypoparathyroidism is scheduled to begin in Q1 2018. The drug has orphan-drug status, which provides expedited trial routes and protection from competition once approved.","partners":null,"customers":null,"investors":"DNA Biomedical Solutions Ltd., Pontifax fund, Kite Pharma","confidence":9,"key_topics":["IPO","merger","investment","drug development","clinical trial"],"date_of_event":"September 13, 2017","valuation_amount":"$94 million","impact_on_company":"growth-positive","investment_amount":"$10 million","structured_issues":["Investment","Acquisition"],"acquisition_amount":null,"structuredIssuesShow":"#Investment  #Acquisition","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"OwPzfCOHSzizIRRnaPQfzLPfHRT9kUQk62BHEqftdsSqy5gnEtJfjJ","news_summary":"Entera Bio raising $10m at $94m valuation","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"353b67a9-dd68-4b75-80db-9030e0d00b3c","date":"Jul 16, 2017","link":"http://www.globes.co.il/en/article-entera-bio-files-for-nasdaq-ipo-1001197354","source":"www.globes.co.il","visible":1,"analysis":{"tags":"IPO","company":"Entera Bio","layoffs":null,"summary":"Entera Bio, a drug development company, has filed a draft prospectus with the US Securities and Exchange Commission (SEC) for a Nasdaq IPO. The company has decided to pursue an IPO instead of merging with Alcobra. The funds raised in the IPO, expected to be in the tens of millions of dollars, will be used for Phase II/III trials of Entera Bios drug for the treatment of Hypoparathyroidism. DNA Biomedical Solutions Ltd., which holds 36% of Entera Bios shares, saw its market cap increase to NIS 43 million. Entera Bio aims for a company valuation of $75 million after the IPO. The IPO is expected to take place in September 2017.","partners":null,"customers":null,"investors":"Capital Point","confidence":9,"key_topics":["Entera Bio","IPO","drug development","Hypoparathyroidism","Phase II/III trials"],"date_of_event":"September 2017","valuation_amount":"$75 million","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Public Trading"],"acquisition_amount":null,"structuredIssuesShow":"#Public Trading","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"L0rLNiqp9GnmYn69WU27mTLImf9Fv6VszgXEFSJsttkGo0wl30ToI6","news_summary":"Entera Bio files for Nasdaq IPO","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"efee149f-5df7-42fd-92c5-16fad970dea2","date":"Jul 24, 2016","link":"http://www.globes.co.il/en/article-entera-bio-raises-75m-1001141522","source":"www.globes.co.il","visible":1,"analysis":{"tags":"pharmaceutical","company":"Entera Bio","layoffs":null,"summary":"Pharmaceutical company Entera Bio has raised $7.5 million in a loan convertible into shares. The investment was led by Pontifax and included participation from private investors, many of whom are associated with immunotherapy company Kite Pharma. The announcement caused a 5% increase in DNA Biomedicals share price and added NIS 42 million to the companys market cap. Entera Bio is developing orally administered drugs, with its leading drug being a treatment for hypoparathyroidism. The company hopes to begin Phase III trials soon. DNA Biomedical owns 51% of Entera Bio.","partners":null,"customers":null,"investors":["Pontifax","private investors"],"confidence":9,"key_topics":["orally administered drug","pulmonary hypertension","loan convertible into shares","private investors","Kite Pharma"],"date_of_event":"July 24, 2016","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$7.5 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"fqbzFi4JkLuz79zoVGBVQLNhOzVZuW291piG6ZGsE0EQuzXs7a2gj1","news_summary":"Israeli drug developer Entera Bio raises $7.5m","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"39ecd823-75e9-4e51-bc48-cead736b9b13","date":"Sep 27, 2012","link":"http://www.globes.co.il/en/article-1000786994","source":"www.globes.co.il","visible":1,"analysis":{"tags":"oral osteoporosis treatment","company":"Entera Bio","layoffs":null,"summary":"Entera Bio, a subsidiary of DNA Biomedical Solutions Ltd., announced favorable interim results of the second stage of its Phase I clinical trial for its oral treatment for osteoporosis. The company successfully achieved the maximum concentration of the active ingredient in the blood, demonstrating the safety and absorption of the drug. Entera Bios oral drug is based on an intravenous drug for osteoporosis and aims to replace the need for injections. The company expects to receive the final results of the clinical trial in a few months and plans to submit an investigational new drug application with the US FDA. The drug on which Entera Bios oral treatment is based had $930 million in sales in 2011.","partners":["DNA Biomedical Solutions Ltd."],"customers":null,"investors":null,"confidence":9,"key_topics":["oral osteoporosis treatment","Phase I clinical trial","drug absorption","investigational new drug application","osteoporosis treatment market"],"date_of_event":"September 27, 2012","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"xfupjYNKLvGHVLmIaCngpJNgpPxA3dpo96s6sOyG5YntUWnY7xDrV7","news_summary":"DNA Biomedical jumps on subsidiary's osteoporosis results","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"b485fe02-0d2f-4721-b9a6-54f9bfde1696","date":"Sep 27, 2011","link":"http://www.firstwordpharma.com/node/911594#axzz3JzLjqxh8","source":"www.firstwordpharma.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"tRABU076LIcCEtcWZVyQFbmfCVREnnmy32jHP9QQjaqxN0eKMkIZjj","news_summary":"Oramed Pharmaceuticals Announces Successful Phase 1 Clinical Trial Results for EnteraBio","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":128,"techcommunityinvolvement":null,"mediagallery":[{"id":"3f7e461c-7da1-4e1f-b6af-f0aad3ed40c4","timestamp":"2018-06-05 18:01:59.000000","resources_type":1,"resources_title":"","resources_file_name":"$D680u53wWo1uVdQrhG6EF0m1VSvW27omSoBq7bsuG3X529oBGcNT8L","alt":"","cleanBucketUrl":"https://storage.googleapis.com/clean-finder-353810","imageurl":"https://storage.googleapis.com/clean-finder-353810/$D680u53wWo1uVdQrhG6EF0m1VSvW27omSoBq7bsuG3X529oBGcNT8L","url":"https://storage.googleapis.com/clean-finder-353810/$D680u53wWo1uVdQrhG6EF0m1VSvW27omSoBq7bsuG3X529oBGcNT8L"}],"tags":["chronic-disease","oral-drugs","pharmaceuticals","drug-delivery","inflammatory-diseases","cancer","osteoporosis","patients","pharma-companies"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA"],"technologysuccessstory":null,"usecases":[],"businessmodels":["B2B"],"productstage":"Clinical Trial","products":["EB612","EB613","OXM","GLP-2","Oral PTH 1-34","Kappa"],"geomarkets":["United States"],"targetmarkets":[],"marketcapital":132880439,"marketcapitaldate":"2025-11-01T14:04:18.000Z","funding":{"investors":7,"lastfunding":"$6.6M","totalrounds":7,"fundingstage":"Public","totalfunding":"$58.9M","publicinvestors":7,"lastpublicfunding":6600000,"totalpublicrounds":7,"totalpublicfunding":58900000},"team":[{"name":"Roger Garceau ","email":"roger@enterabio.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4K2ti4UKDA","bounced":true,"claimed":0,"founder":0,"urlname":"roger-garceau","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgnbq5gAoM","position":"Board Member","last_name":"Garceau ","claimtoken":"glTkhHB40YCrfyTuM1Wt7a0URZNTaowegHDIN3OGhV1GgyaAdfOFwo","first_name":"Roger","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/roger-garceau-5460371/","unsubscribed":false,"is_activeuser":1,"additionalemail":"garceau.roger@enterome.com","claimedemaildate":"2024-01-15 17:40:53.000000","initials":"RG","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Miranda  Toledano","email":"miranda@enterabio.com","phone":"","gender":"Female","userid":"QHCz2DkLwbRO2VT99WyWWURptRTVibbwBudb9wCqk2Hnm5OCtCuhOV","bounced":false,"claimed":null,"founder":0,"urlname":"miranda-toledano","visible":1,"memberid":"jl6U3xUYpSM1G4VHREDlU1diZJP4NKmZNkYaLSTzIx1C5RCOEtmp30","position":"CEO","last_name":"Toledano","claimtoken":"z0ANYAd1cRXJUUk80wdYg511OFLYrJmLLDv2pCBPoyPNHqGJfwq57A","first_name":"Miranda ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/miranda-toledano-a4060721/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2024-01-15 17:41:04.000000","initials":"MT","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Hillel Galitzer","email":"hillel@enterabio.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoMnx2KEKDA","bounced":false,"claimed":0,"founder":0,"urlname":"hillel-galitzer","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICgyYfk1goM","position":"COO","last_name":"Galitzer","claimtoken":"HtlbDc3drxh6HQbT9qgdGb8r4BochHRElRkBWfXovggM02plsZBfI1","first_name":"Hillel","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/hillelgalitzer","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2024-01-15 17:41:07.000000","initials":"HG","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Pharmaceuticals","sectorverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgPGylJ0IDA","fullname":"Natalia Golczar"},"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgMGgoMMJDA","fullname":"Yanina Wainscheinker"},"biverifydate":"2020-02-04T00:00:00.000Z","crunchbaseid":"entera-bio","lastupdator":"Yanina Wainscheinker","lastupdator_email":"yanina.wainscheinker@sncentral.org","creator":null,"creator_email":null,"createdate":"2014-11-24T00:00:00.000Z","biverification":"Yanina Wainscheinker","sectorverification":"Natalia Golczar","affiliatedOrganizations":null,"timeline":[{"id":"X70pA4Ng9vUaOWUCbsk95X8iAvlE8HwHmS5qDawMJNfsomfzkk1NZ7","date":"Dec 2023","amount":"$6.6M","source":"https://www.globenewswire.com/en/news-release/2023/12/26/2801081/0/en/Entera-Bio-Announces-Closing-of-Private-Placement-Extends-Cash-Runway-into-2025.html","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"PIPE","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":6600000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODmj-_eCAw","date":"Dec 2019","amount":"$14.3M","source":"From the founder & CEO","eventtype":"FundingRoundEvent","investment":[{"name":"Undisclosed Investor(s)","type":"Investor","amount":0,"hidden":false,"country":"Europe","fullurl":"/investor_page/undisclosed-investor-s","logokey":null,"tagline":"","urlname":"/investor_page/undisclosed-investor-s","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCE3L3CCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"07d8927e-8c53-44eb-93ba-310fb92dfc9b","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":"Follow on "},{"name":" D.N.A Biomedical Solutions Ltd","type":"Company","amount":0,"hidden":true,"country":"Israel","fullurl":"/company_page/d-n-a-biomedical-solutions-ltd-1","logokey":null,"tagline":"","urlname":"/company_page/d-n-a-biomedical-solutions-ltd-1","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOD9lcvgCQw","fundingtype":"Company","leadpartner":null,"investmentid":"4495b3d4-03d1-4698-aee3-fbccf716644c","fundingsubtype":"","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/startups-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"PIPE","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":14300000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOC4jubYCgw","date":"Oct 2018","amount":"$12.5M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Undisclosed Investor(s)","type":"Investor","amount":0,"hidden":false,"country":"Europe","fullurl":"/investor_page/undisclosed-investor-s","logokey":null,"tagline":"","urlname":"/investor_page/undisclosed-investor-s","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCE3L3CCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"50bebafa-9053-44a7-ad42-70e5ab2de0f6","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"PIPE","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":12500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCot9byCgw","date":"Jul 2018","amount":"Undisclosed","source":"","ticker":"ENTX","eventtype":"POEvent","valuation":"$91M","investment":[],"capitalraised":"$11M","stockexchange":"NASDAQ","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCIutD_CQw","stockexchange_logokey":"$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","exit_label":"EXIT","po_label":"Initial Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":11000000,"valuationnumber":91000000},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCko8SbCQw","date":"Oct 2017","amount":"$2M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Pontifax","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/Pontifax","logokey":"$8HWp0ziD5Hcmj6wqEIHQTrElz5KthIPEOZM39F7kKUQRFzC0JbmnmH","tagline":null,"urlname":"/investor_page/Pontifax","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgOfWjoAKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"0cc5e442-5147-4d86-9fa3-98b62215d6cd","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$8HWp0ziD5Hcmj6wqEIHQTrElz5KthIPEOZM39F7kKUQRFzC0JbmnmH","leadcaption":"","followupcaption":"Follow on "}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":2000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCkmqn6CAw","date":"Jul 2016","amount":"$7.5M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"David Bonderman","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/david-bonderman","logokey":"$4h44O3hjY4urRq2wkePCSugGmxZERjsZyeD2eYQrLbaDonUWg81FMr","tagline":"","urlname":"/investor_page/david-bonderman","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOD42ffWCAw","fundingtype":"Angel","leadpartner":null,"investmentid":"4807b3dc-bcb1-4fd2-ba22-d4f80fc3e29e","fundingsubtype":"Angel","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$4h44O3hjY4urRq2wkePCSugGmxZERjsZyeD2eYQrLbaDonUWg81FMr","leadcaption":"","followupcaption":""},{"name":"Pontifax","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/Pontifax","logokey":"$8HWp0ziD5Hcmj6wqEIHQTrElz5KthIPEOZM39F7kKUQRFzC0JbmnmH","tagline":null,"urlname":"/investor_page/Pontifax","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgOfWjoAKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"6f5385cc-83d7-4d11-8ffd-d5c9cd8c6be2","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$8HWp0ziD5Hcmj6wqEIHQTrElz5KthIPEOZM39F7kKUQRFzC0JbmnmH","leadcaption":"","followupcaption":""},{"name":"Arie Belldegrun","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/arie-belldegrun","logokey":"$0SxPsrqDpwK7CG5Jh38N6tnUVcJuFxVXaECzNhK1xXtSe2IvcxWaOG","tagline":"","urlname":"/investor_page/arie-belldegrun","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOD42-yKCww","fundingtype":"Angel","leadpartner":null,"investmentid":"dd7be56d-0c4f-48b3-9f58-4f975d8408ea","fundingsubtype":"Angel","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$0SxPsrqDpwK7CG5Jh38N6tnUVcJuFxVXaECzNhK1xXtSe2IvcxWaOG","leadcaption":"","followupcaption":""},{"name":"Joshua Kazam","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/joshua-kazam","logokey":"$LgV3xnar90Ado8dSV0s0Diql01mKZgBVEsrr16TYGtnVnfdRo02Cnb","tagline":"","urlname":"/investor_page/joshua-kazam","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODE1YPvCgw","fundingtype":"Angel","leadpartner":null,"investmentid":"f0082500-191c-4b59-85b4-4940286ef80f","fundingsubtype":"Angel","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$LgV3xnar90Ado8dSV0s0Diql01mKZgBVEsrr16TYGtnVnfdRo02Cnb","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Convertible Debt","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":7500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODknsDNCAw","date":"Feb 2014","amount":"$5M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Kenneth Abramowitz","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/kenneth-abramowitz","logokey":"$aKKLipCMBRjJtaH75oUojt79PFGJFStq2ZmMvlgwtTdpGumqEYE9YR","tagline":"","urlname":"/investor_page/kenneth-abramowitz","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEyJm0CAw","fundingtype":"Angel","leadpartner":null,"investmentid":"41c54ee2-9b1e-4674-a789-8578d2e6dca7","fundingsubtype":"Angel","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$aKKLipCMBRjJtaH75oUojt79PFGJFStq2ZmMvlgwtTdpGumqEYE9YR","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":5000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"9/2009","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"Entera Bio","logourl":"https://storage.googleapis.com/clean-finder-353810/$dPDIlWRLTZPzFYrk5wjDddJeYOndAY3kDe5t1AJyKWnS1JMBI8r5Dy","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$dPDIlWRLTZPzFYrk5wjDddJeYOndAY3kDe5t1AJyKWnS1JMBI8r5Dy","seoabout":"Entera Bio is a product-focused biotechnology company specializing in the oral delivery of large molecules and biologics.\nThe company currently conducts cl...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":3,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drug Delivery","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gKDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Molecules","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"},{"depth":3,"name":"Biotechnology","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Patients","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drug Delivery#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA>Patients#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA>Molecules#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drug Delivery#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gKDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA/Patients#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA|2:>TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA/Molecules#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Drug Delivery","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drug Delivery"},{"title":"Drugs Discovery & Development","key":"0-0-0-1","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drugs Discovery & Development"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Life Sciences","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Pharmaceuticals","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Pharmaceuticals"},{"title":"Biotechnology","key":"0-0-0-1","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Biotechnology"}]},{"title":"Healthcare","key":"0-0-1","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare","children":[{"title":"Patients","key":"0-0-1-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare>Patients"}]}]}],"coreTechnology":[{"title":"Biologicals","key":"0-0","path":"TechnologyClassificationModel>Biologicals","children":[{"title":"Molecules","key":"0-0-0","path":"TechnologyClassificationModel>Biologicals>Molecules"}]}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drug Delivery","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gKDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Molecules","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"},{"depth":3,"name":"Biotechnology","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Patients","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Drug Delivery","Drugs Discovery & Development"],"coreTechnology":["Biologicals","Molecules"],"targetCustomer":["Healthcare & Life Sciences","Life Sciences","Pharmaceuticals","Biotechnology","Healthcare","Patients"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"none","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCot9byCgw","date":"Jul 2018","amount":"Undisclosed","source":"","ticker":"ENTX","eventtype":"POEvent","valuation":"$91M","investment":[],"capitalraised":"$11M","stockexchange":"NASDAQ","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCIutD_CQw","stockexchange_logokey":"$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","exit_label":"EXIT","po_label":"Initial Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":11000000,"valuationnumber":91000000}],"privateequityfunding":[{"id":"X70pA4Ng9vUaOWUCbsk95X8iAvlE8HwHmS5qDawMJNfsomfzkk1NZ7","date":"Dec 2023","amount":"$6.6M","source":"https://www.globenewswire.com/en/news-release/2023/12/26/2801081/0/en/Entera-Bio-Announces-Closing-of-Private-Placement-Extends-Cash-Runway-into-2025.html","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"PIPE","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":6600000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODmj-_eCAw","date":"Dec 2019","amount":"$14.3M","source":"From the founder & CEO","eventtype":"FundingRoundEvent","investment":[{"name":"Undisclosed Investor(s)","type":"Investor","amount":0,"hidden":false,"country":"Europe","fullurl":"/investor_page/undisclosed-investor-s","logokey":null,"tagline":"","urlname":"/investor_page/undisclosed-investor-s","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCE3L3CCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"07d8927e-8c53-44eb-93ba-310fb92dfc9b","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":"Follow on "},{"name":" D.N.A Biomedical Solutions Ltd","type":"Company","amount":0,"hidden":true,"country":"Israel","fullurl":"/company_page/d-n-a-biomedical-solutions-ltd-1","logokey":null,"tagline":"","urlname":"/company_page/d-n-a-biomedical-solutions-ltd-1","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOD9lcvgCQw","fundingtype":"Company","leadpartner":null,"investmentid":"4495b3d4-03d1-4698-aee3-fbccf716644c","fundingsubtype":"","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/startups-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"PIPE","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":14300000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOC4jubYCgw","date":"Oct 2018","amount":"$12.5M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Undisclosed Investor(s)","type":"Investor","amount":0,"hidden":false,"country":"Europe","fullurl":"/investor_page/undisclosed-investor-s","logokey":null,"tagline":"","urlname":"/investor_page/undisclosed-investor-s","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCE3L3CCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"50bebafa-9053-44a7-ad42-70e5ab2de0f6","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"PIPE","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":12500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCko8SbCQw","date":"Oct 2017","amount":"$2M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Pontifax","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/Pontifax","logokey":"$8HWp0ziD5Hcmj6wqEIHQTrElz5KthIPEOZM39F7kKUQRFzC0JbmnmH","tagline":null,"urlname":"/investor_page/Pontifax","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgOfWjoAKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"0cc5e442-5147-4d86-9fa3-98b62215d6cd","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$8HWp0ziD5Hcmj6wqEIHQTrElz5KthIPEOZM39F7kKUQRFzC0JbmnmH","leadcaption":"","followupcaption":"Follow on "}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":2000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCkmqn6CAw","date":"Jul 2016","amount":"$7.5M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"David Bonderman","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/david-bonderman","logokey":"$4h44O3hjY4urRq2wkePCSugGmxZERjsZyeD2eYQrLbaDonUWg81FMr","tagline":"","urlname":"/investor_page/david-bonderman","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOD42ffWCAw","fundingtype":"Angel","leadpartner":null,"investmentid":"4807b3dc-bcb1-4fd2-ba22-d4f80fc3e29e","fundingsubtype":"Angel","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$4h44O3hjY4urRq2wkePCSugGmxZERjsZyeD2eYQrLbaDonUWg81FMr","leadcaption":"","followupcaption":""},{"name":"Pontifax","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/Pontifax","logokey":"$8HWp0ziD5Hcmj6wqEIHQTrElz5KthIPEOZM39F7kKUQRFzC0JbmnmH","tagline":null,"urlname":"/investor_page/Pontifax","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgOfWjoAKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"6f5385cc-83d7-4d11-8ffd-d5c9cd8c6be2","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$8HWp0ziD5Hcmj6wqEIHQTrElz5KthIPEOZM39F7kKUQRFzC0JbmnmH","leadcaption":"","followupcaption":""},{"name":"Arie Belldegrun","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/arie-belldegrun","logokey":"$0SxPsrqDpwK7CG5Jh38N6tnUVcJuFxVXaECzNhK1xXtSe2IvcxWaOG","tagline":"","urlname":"/investor_page/arie-belldegrun","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOD42-yKCww","fundingtype":"Angel","leadpartner":null,"investmentid":"dd7be56d-0c4f-48b3-9f58-4f975d8408ea","fundingsubtype":"Angel","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$0SxPsrqDpwK7CG5Jh38N6tnUVcJuFxVXaECzNhK1xXtSe2IvcxWaOG","leadcaption":"","followupcaption":""},{"name":"Joshua Kazam","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/joshua-kazam","logokey":"$LgV3xnar90Ado8dSV0s0Diql01mKZgBVEsrr16TYGtnVnfdRo02Cnb","tagline":"","urlname":"/investor_page/joshua-kazam","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODE1YPvCgw","fundingtype":"Angel","leadpartner":null,"investmentid":"f0082500-191c-4b59-85b4-4940286ef80f","fundingsubtype":"Angel","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$LgV3xnar90Ado8dSV0s0Diql01mKZgBVEsrr16TYGtnVnfdRo02Cnb","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Convertible Debt","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":7500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODknsDNCAw","date":"Feb 2014","amount":"$5M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Kenneth Abramowitz","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/kenneth-abramowitz","logokey":"$aKKLipCMBRjJtaH75oUojt79PFGJFStq2ZmMvlgwtTdpGumqEYE9YR","tagline":"","urlname":"/investor_page/kenneth-abramowitz","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEyJm0CAw","fundingtype":"Angel","leadpartner":null,"investmentid":"41c54ee2-9b1e-4674-a789-8578d2e6dca7","fundingsubtype":"Angel","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$aKKLipCMBRjJtaH75oUojt79PFGJFStq2ZmMvlgwtTdpGumqEYE9YR","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":5000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[],"merger_acquisitions":[],"others":[]}}